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ABSTRACT 
 
 
Peter Benjamin Uthe:  The Development of Polycationic Materials for Gene Delivery 
Applications 
 
 
(Under the direction of Dr. Valerie Sheares Ashby) 
 
 
Polycationic materials were designed to serve as vehicles for the delivery of 
therapeutic DNA into cells.  Three areas were explored including ionization and 
buffering control, degradable scaffolds, and new functionality for enhanced cellular 
uptake.  It was found that the delivery ability was greatly influenced by the ionization 
state of the materials with a range (24 - 50% ionization at a pH of 7.4) defined as a target 
in the development of future materials.  Use of a degradable scaffold was found to be 
successful in reducing unwanted toxicity that is present in most delivery vehicles 
developed to date.  Lastly, synthetic strategies were developed for integrating a new 
functionality, with proven cellular uptake enhancement, into monomers and polymers.  
Through this work, fundamental studies were conducted that established material design 
guidelines as well as supported strategies for controlling toxicity and enhancing 
bioactivity.  
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Chapter 1.  An Introduction to Gene Therapy 
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1. Introduction to Gene Therapy 
 The ability to activate, silence, or introduce gene expression is a powerful tool for 
the treatment of diseases.1  One method to accomplish this is to introduce foreign 
therapeutic DNA to a desired location so that it may affect a target gene.  There is a broad 
range of techniques for delivery including direct introduction of naked DNA, use of 
modified viruses, or developing synthetic strategies.2 The first uses an external driving 
force, such as particle bombardment, magnetic fields, or electric fields, to promote 
membrane translocation.  The latter two approaches incorporate vehicles, or vectors, that 
contain and protect the DNA, promote cellular uptake, and ultimately release the cargo at 
the nucleus. 
 
1.1 Delivery.   
To frame gene delivery, the biological pathway and barriers need to be 
introduced.  Administration can occur peripherally (e.g. oral, airway, intravenous) or 
locally (e.g. implant, local injection).  If there is global administration of the DNA, it 
must circulate through the body, avoid premature clearance (e.g. reticuloendothelial 
system (RES)), resist nuclease degradation, and accumulate near the target location.3,4  
Site accumulation can either go through nonspecific interactions, passive targeting such 
as the enhanced permeability and retention effect (EPR effect), or active targeting of 
specific cell types.4,5  Delivery can also be accomplished by local administration, but 
complications arise from invasive procedures for implants or injections into the target 
location.  Once at the site, the DNA must associate to the cell membrane via cell 
receptor/targeting ligands, electrostatic interactions, or hydrophilic interactions, and 
3 
 
translocate into an intracellular compartment (Figure 1.1).  If it is taken up through 
endocytosis, it must escape from the endosome prior to degradation.  The next hurdle is 
passing through the cytosol followed by nuclear uptake and ultimately transcription and 
translation to produce the therapeutic protein. 
 
 
Figure 1.1. Specific and non specific cell membrane interactions that lead to cellular uptake; I-II) 
receptor mediated; III) electrostatic; IV) hydrophobic6 
 
1.1.1 Naked DNA Delivery.   
The exact pathway for delivery is dependent on the vector chosen, which can be 
categorized into three main types.  The first is direct delivery of naked DNA, the second 
is viral based delivery, and the third is non-viral delivery.  In the case of naked DNA 
delivery, the DNA enters the cell through an external force that either penetrates the cell 
membrane or disrupts it to permit the passage of larger molecules.  Particle bombardment 
techniques such as the gene gun or jet injection use high velocity particles or media that 
Targeted Uptake Nonspecific 
Uptake 
I 
II III 
IV lipophilic ligands 
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are capable of penetrating a target tissue.2  Cellular uptake of naked DNA has also been 
enhanced by using electroporation, sonoporation, or use of a magnetic field.2  The 
mechanism for electroporation consists of two parts.  The first is an electric field that 
induces accumulation near the cell membrane via electrophoretic mobility.  The current 
also disrupts the cell membrane on a microscopic scale which allows for passage across 
the membrane.  Sonoporation causes cavitation around the target site that enhances 
membrane permeability. 2  Lastly, delivery has been enhanced by tethering the cargo to 
magnetic particles and applying a magnetic field.  In naked DNA delivery there is no 
protection of the DNA from nuclease degradation and these pathways suffer from low 
efficiency.  Furthermore the application of the delivery is often limited to superficial 
tissues, small target sites, and/or is accompanied with invasive procedures. 
 
1.1.2 Viral Delivery.   
Viral vectors are typically derived from retroviruses and adenoviruses, and are 
formed from partial or complete replacement of the viral wild-type DNA.  The viral 
machinery has evolved to impart high target specificity, cellular uptake, and nuclear 
localization resulting in high transfection efficiency.7  In this system translocation occurs 
by either a signaling pathway or direct membrane fusion (Figure 1.1).  Once taken up into 
the cell, the vector is contained in an endosome and escape occurs via endosomal 
disruption proteins or membrane fusion.  The vectors then travel through the cytosol to 
the nucleus, and the genetic material is taken up into the nucleus.  Viruses, once again, 
have evolved to utilize the natural machinery of the cell to be actively taken to the 
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nucleus through nuclear localizing proteins (NLP).  They then utilize nuclear pores to 
transfer the cargo into the nucleus.  
The most common viral vectors that have been developed are the adeno-
associated virus, herpes virus, pox virus, and lentivirus.7  Retroviral vectors randomly 
insert DNA into the host chromosome and results in persistent gene expression.  An issue 
arises however if the insertion occurs at an integral site, interrupting protein expression, 
and potentially leading to oncogenic effects.  Adenoviral vectors do not insert DNA into 
the host chromosomes, but as a result only yield short term gene expression.  In both 
systems the body can gain natural immunity and elicit inflammatory or immunological 
responses.  Despite the high transfection efficiency, viral type vectors have resulted in 
cancer and death, and have not been able to move beyond phase III clinical trials.8,9 
 
1.1.3 Synthetic Vector Delivery.   
Synthetic vectors are being designed in an attempt to utilize the positive 
characteristics of the other classes of delivery and avoid the negative effects such as 
ineffective administration and severe health risks.  These materials are designed to form a 
complex with DNA (polyplex) usually through electrostatic interactions between cationic 
functional groups on the vector with the anionic phosphate groups along the DNA 
backbone.2  Synthetic vectors typically possess primary, secondary, and/or tertiary amino 
groups that maintain protonated and unprotonated amines.  In the polyplex, DNA is 
highly compacted, allowing for membrane translocation and protection from degradation 
by nuclease enzymes.3 Non-viral vectors have the advantage of carrying large DNA 
structures with lower safety risks.1,2,6 These vectors can also be synthesized in large 
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quantities, which aids in commercialization. Various topologies have been utilized 
including linear, branched, hyperbranched, and dendritic materials as well as liposomes 
and micelles.4,6,8,9 The greatest disadvantages in synthetic delivery are non-specific 
toxicity associated with polycationic materials as well as typically low transfection 
efficiency.   
 
Figure 1.2. Transfection pathway from complex formation to gene expression; I) complex 
formation; II) translocation; III) endosomal escape; IV) polymer/DNA dissociation; V) nuclear 
uptake; VI) gene expression6 
 
As depicted in Figure 1.2, synthetic vectors go through a similar pathway to viral 
vectors.  Attachment of signaling ligands can induce cellular uptake or they can go 
through nonspecific membrane association via electrostatic or hydrophobic interactions 
(Figure 1.1).  They are then taken up into the cell through endocytosis.  Vectors then 
escape from the endosome, and to achieve this, endosomal disruption proteins or more 
prominently the ‘proton sponge’ effect have been utilized (Figure 1.3).  Briefly, cationic 
II 
III 
IV 
endosome 
lysosome 
nucleus V 
VI 
I 
protein 
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materials have a distribution of charged and uncharged functional groups, typically 
amines.  Upon endosomal acidification, the neutral amines become protonated, 
effectively buffering the endosome and increasing the internal charge potential.  This 
induces chloride diffusion into the vesicle followed by osmotic swelling that leads to 
membrane rupture and cargo release.  Once in the cytosol the cargo must be delivered to 
the nucleus.  Synthetic vectors have been modified with nuclear localizing peptides to 
take advantage of the natural cellular machinery that actively moves the polyplex to the 
nucleus.  Passive diffusion of large particles in the cytosol in very difficult, and it is 
generally thought to not be the mode of transport if no NLP is present.  To date the exact 
pathway has not been elucidated to date.  It is also important to note that nuclear uptake 
of synthetic materials typically occurs during cell replication when the nuclear membrane 
is dissolved, adding another limitation of synthetic vectors by making them cell cycle 
dependent. 
 
 
Figure 1.3.  ‘Proton sponge’ theory of endosomal release; I) early endosome; II) acidification and 
chloride accumulation; III) osmotic swelling and membrane rupture3 
 
I II III 
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A variety of synthetic methods has been employed to complex and protect DNA 
including liposomes, micelles, and functionalized polymers.  The first two systems utilize 
amphiphilic materials that encapsulate the DNA.  They have the advantage of low 
toxicity and facile surface functionalization.  The greatest disadvantage in these systems 
is their lower structural stability of the complex and their susceptibility to disruption and 
premature DNA release.  A great focus of gene therapy has been in the research of 
micelles and liposomes and many reviews have been written on these subjects.10,11  The 
remainder of the research reviewed herein will focus on polymeric systems. 
 
1.2 Non-Degradable Materials 
 1.2.1 Poly(ethyleneimine)  
Polymeric synthetic vectors can be divided into nondegradable synthetic 
materials, degradable synthetic materials, and biologically derived materials.  The most 
prominent nondegradable material has been poly(ethyleneimine) (PEI).  Branched (b-
PEI) and linear (l-PEI) topologies have been synthesized, the branched from acid 
catalyzed polymerization of aziridine, and the linear from ring opening polymerization of 
2-ethyl-2-oxazoline followed by hydrolysis (Figure 1.4).12   
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Figure 1.4.  Synthesis and structure of a) branched PEI (b-PEI) and b) linear PEI (l-PEI) 
 
The material is one of the most physically and biologically characterized delivery 
vehicles, and due to the high efficiency, it has become a standard in the field.  The 
branched form contains 1o, 2o, and 3o amines in a ratio of 1:1:1 respectively.13  The linear 
form has mainly 2o amines.  The acid/base profiles for each system show a sloped pH 
transition between a pH of 5-8 showing multiple pKa values for the amines present in the 
polymers.14  With a range of pKa values the branched form of PEI has 20% amine 
protonation at biological pH (pH 7.4) leaving a significant proportion of the amines 
unprotonated and allowing for a large buffering capacity.  This ‘proton sponge’ effect is 
attributed to efficient endosomal escape and ultimately the high transfection of PEI. 
There have been studies of the influence of topology, molecular weight, 
percentage of amines, and modified chemical composition on the overall transfection 
efficiency and toxicity.  The biological properties and activity of PEI have been shown to 
be dependent on polymer topology.  The branched form, with its array of amine types, 
formed more stable complexes than the linear form.15  Furthermore, b-PEI contains 
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tertiary amines that impart a greater buffering potential than l-PEI.14  Despite these 
properties, l-PEI has shown high in vivo transfection efficiency16,17, and derivatives of 
this form are more prominent in commercially available gene delivery vehicles, e.g. 
ExGen500 and jetPEI.  The high efficiency has been attributed to the ability of l-PEI to 
mediate cell-cycle independent nuclear delivery18 as well as possessing lower complex 
stability that permits DNA dissociation once the target site has been reached.   
  The molecular weight of PEI also plays an important role in its transfection 
efficiency.  Godbey et al. demonstrated that in a series of PEIs ranging from 600 to 
70,000 Da the transfection efficiency increased as the molecular weight increased.19  
They also reported that the toxicity increased as the molecular weight increased.  Kunath 
et al. demonstrated the use of low molecular weight PEI (5400 Da; LMW-PEI) that had a 
2.1-110 fold increase in transfection efficiency (cell line dependent) compared to a 
commercially available high molecular weight PEI (25,000 Da; HMW-PEI).20  The 
toxicity for LMW-PEI was also relatively low.  To attain the high transfection 
efficiencies the concentration of LMW-PEI was optimized at an N/P ratio of 67, where as 
the optimal N/P ratio of HMW-PEI is 6.7.  The lower toxicity of LMW-PEI enabled the 
use of higher polymer concentration.  Werth et al. demonstrated the use of lower 
molecular weight PEI obtained from fractionation of commercial PEI (25,000 Da) and 
showed that the low molecular weight fraction was able to efficiently deliver siRNA into 
a range of carcinoma cell lines, to which the commercially available PEI could not.21  
Once again the concentration for optimized delivery was at an N/P ratio of 66.  In general 
the lower molecular weight materials were less toxic but required much higher effective 
concentrations. 
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Figure 1.5. a) alkylated PEI; b) acylation of PEI with acetic anhydride 
 
To capitalize on the high bioactivity and reduce the toxicity, modifications such 
as N-alkylation and N-acylation, pegylation, or degradation have been used.  Klibanov 
has shown that N-alkylation of the 1o and 2o amines (Figure 1.5) decreased the 
transfection efficiency of 25 kDa branched PEI, but alkylation of the 3o amines enhanced 
activity.22  This observation was attributed to the position of alkylation with the 1o and 2o 
amines located at the periphery of the material and the 3o amines more internalized.  In 
solution the hydrophobic alkyl groups placed at the surface collapse the structure, 
shielding the interior amines.  Since the 3o amines are already internalized, alkylation of 
the 3o amines preserved the overall structure and increased transfection efficiency.  Akinc 
et al. demonstrated that quaternization of all of the amines enhances complex formation 
and cell internalization, but due to the loss of buffering ability, overall transfection was 
greatly diminished.23  The transfection of this material increased when the endosomal 
buffering compound, chloroquin, was present and was one example that supports the 
‘protein sponge’ theory for endosomal release. 
In an attempt to decrease the toxicity stemming from the 1o amines, and to a lesser 
degree 2o amines, N-acylation has also been employed (Figure 1.5).  Pack has shown that 
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partial acetylation of up to 57% of the primary amines of b-PEI with acetic anhydride, 
has a 58-fold increase in transfection efficiency in HEK293 cells.24,25  Despite a decrease 
in buffering capacity, the bioactivity was enhanced.  This was attributed to a decrease in 
binding strength, facilitating DNA dissociation upon delivery.  On the other hand, 
Thomas et al. demonstrated that in commercially available 25 kDa l-PEI, the material is 
only 89% deacylated as received.26  When the remaining 11% of the amides were 
hydrolyzed, the efficiency was enhanced by 21-fold in vitro, and 10,000-fold in vivo.  
The buffering capacity of l-PEI at biological pH was known to be less than b-PEI, and it 
was concluded that the enhanced transfection efficiency stemmed from its increase.  
Alkylation and acylation demonstrated the balance of charge, toxicity, binding, and 
buffering that is required in developing vector.  Branched PEI was enhanced by 
decreasing the number of the more toxic and stronger binding 1o and 2o amines, while 
linear PEI, with primarily 2o amines, benefited from increasing the buffering capacity. 
 
 
Figure 1.6.  Acid labile PEG grafts conjugated to branched PEI 
 
Modifications such as incorporating PEG blocks or degradability have been used 
to decrease the cytoxicity of PEI.  PEG has been widely used in biological applications 
due to its biocompatibility, hydrophilicity, and stealth like properties.  When a block 
copolymer with PEG and PEI (PEI-b-PEG) is used, the cationic block condenses the 
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DNA resulting in charge neutralization.  PEG then orients itself to the periphery forming 
a micelle and internally shields the polycation/DNA complex from premature clearance 
via macrophage or the reticuloendothelial system.  When no other modifications to the 
block copolymers are used such as degradable groups or targeting ligands, PEG decreases 
surfaces interactions, which results in higher circulation times and lower toxicity, but also 
prevents membrane association and internalization.27  To avoid the limited transfection 
ability of PEGylated complexes, ether chains have been conjugated to PEI via labile 
groups that facilitate deshielding of the polyplex once internalized into the cell (Figure 
1.6).28,29  This strategy coupled with attaching targeting ligands to promote cellular 
uptake has been a promising for gene delivery.  Shuai et al. have synthesized a series of 
PEG-polycaprolactone grafted b-PEIs (Figure 1.7).30  The transfection efficiency was 
directly related to the PEI molecular weight as well as to the grafting density with higher 
molecular weight PEI (25 kDa vs 800 Da) and lower grafting density showing optimal 
bioactivity.  The toxicity of the degradable materials was less than the nondegradable 
parent materials, but also higher concentrations were required to reach comparable or 
better transfection efficiency. 
 
 
Figure 1.7. a)  Linear PEI containing redox active disulfide linkages in the main chain; b)  
Branched PEI with PEG-b-PCL degradable grafts 
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Another strategy for reducing the toxicity of PEI has been crosslinking or chain 
extension of low molecular weight PEI (< 10 KDa) with a degradable moiety.  Lee et al. 
synthesized linear PEI (800 Da) that contained a reducible disulfide group in the 
backbone (Figure 1.7).  They found that the reducible PEI was nontoxic, but the 
transfection efficiency was less than the 25 kDa PEI control used in the experiments.31  
There are numerous examples of modifications similar to those reported above, and some 
of those can be found in recent reviews.3,4,11 
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Figure 1.8. a) Radical polymerization of N,N-dimethylaminoethylmethacylate 
(DMAEMA); b) PDMAEMA-co-PEGMA; c) PDMAEMA-b-PCMA 
 
A wide range of polymers have been synthesized from chain-growth 
polymerization of amine bearing acryloyl and acrylamido monomers.  The advantages of 
these systems are the facile polymerization via radical or anionic polymerization, most 
were commercially available, and access to a large range of functionality.  One of the 
most promising of the acryloyl based systems is poly[(dimethylamino)ethyl 
methacrylate] (PDMAEMA).  Polymerized via aqueous radical polymerization with an 
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ammonium peroxydisulfate initiator, a <Mn> of 45 x103 g/mol and <Mw> of 36 x 104 
g/mol were attained (Figure 1.8).32  It was found that the transfection efficiency was 
optimized at a w/w ratio of 6-13/1 and the efficiency was serum independent.33  At the 
optimum concentration the transfection was comparable to commercially available 
Lipofectin®.  Despite having promising activity, focus has been on developing 
copolymers to decrease the toxicity. 
Similar to the strategies employed in reducing to the toxicity of PEI, acryloyl 
copolymers have been synthesized that incorporate biocompatible functional groups, 
and/or degradability.  Stolnik developed a series of DMAEMA/PEG-methacrylate 
(PEGMA) copolymers (Figure 1.8) and studied the effects of architecture and PEGMA 
chain length on toxicity, cell internalization and transfection.  It was found that 
incorporating the ethylene glycol segments stabilized the complexes with DNA and 
decreased toxicity compared to PDMEMA.34  Interestingly, the larger PEGMA (45 repeat 
units) had higher cell association and internalization compared to the short chain PEGMA 
(7-8 repeat units) containing material.35  The overall transfection compared to the parent 
compound was lower, and this was attributed to a decrease in cell interactions and 
internalization.36  Lam et al. developed a biocompatible stabilizer, phosphorylcholin 
methacrylate (PCMA) (Figure 1.8), which was also designed to shield the cationic charge 
and stabilize complex formation.37  The zwitterionic group decreased non-specific cell 
association and transfection efficiency, and it was proposed that cell targeting ligands 
functionalized at the periphery would be promising for a low toxicity, cell specific gene 
delivery vehicle.  
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Figure 1.9.  PHEMA with PDMAEMA grafted through a hydrolyzable carbonate linkage 
 
Another strategy to partially shield the positive charge and decrease toxicity is 
incorporation of hydroxyl groups.  Jiang et al. synthesized a PDMAEMA grafted 
poly(hydroxymethyl acrylate) (PHEMA) using a carbonate linkage (Figure 1.9).38  The 
PDMAEMA grafts were capable of condensing DNA while PHEMA effectively 
decreased toxicity.  Furthermore, the carbonate linkages imparted degradability and 
combined with using short chain PDMAEMA grafts the toxicity was decreased.  The 
carbonate linkages hydrolyze rapidly at a pH of 5.0 and are much more stable at a pH of 
7.4.  Prior to hydrolysis, the material behaves similarly to high molecular weight 
PDMAEMA, but once degraded in the endosome, low toxicity PDMAEMA oligos are 
formed.  Transfection efficiency was highest with increased PDMAEMA graft density 
while simultaneously decreasing toxicity. 
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Figure 1.10.  top: Thermoresponsive PNIPAM-co-PDMAEMA-co-PBMA; bottom: Temperature 
controlled complex formation and deformation utilized for dynamic delivery system 
 
PDMAEMA has also been used in copolymers with poly(acylamide)s.  Kurisawa 
et al. synthesized a thermoresponsive copolymer poly(N-isoproylacrylamide) (PNIPAM)-
co-PDMAEMA-co-poly(butyl methacrylate) (PBMA) that utilized the DNA condensing 
ability of PDMAEMA with the thermorepsonsive character of PNIPAM (Figure 1.10).39  
As a homopolymer, PNIPAM has a lower critical solution temperature (LCST) of 32 oC.  
At a temperature below the LCST, the polymer remains hydrophilic and water soluble.  
Above 32 oC water molecules hydrogen bound to the amides disassociate and new 
hydrogen bonds form between the polymer chains.  This causes the polymers to 
aggregate and fall out of solution.  By incorporating a thermoresponsive segment with a 
cationic polymer, the association/dissociation parameters with DNA were controlled.  
Water soluble polyplexes were formed below the LCST.  The temperature was then 
raised to promote tight hydrophobic polyplex aggregates.  At this step the DNA 
disassociation remained very low.  It was then shown that cells could be transfected 
above the LCST, and after a sufficient amount of time, the temperature was reduced, 
causing a thermal switch that promoted DNA dissociation.  The efficiency of the 
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copolymer was enhanced by using the thermal program, and efficiencies greater than 
poly(L-lysine), but lower than PDMAEMA were observed. 
 
 
Figure 1.11.   Thermoresponsive pentablock hydrogel used for persistent DNA delivery 
 
Mallapragada demonstrated another delivery system utilizing a thermal switch to 
promote cotrolled release of a polymer/DNA complex (Figure 1.11).40  A pentablock was 
synthesized, poly(diethylaminoethyl methacryalate) (PDEAEMA)-b-poly(ethyleneoxide) 
(PEO)-b-poly(propyleneoxide) (PPO)-b-PEO-b-PDEAEMA, that took advantage of the 
condensing ability of PDEAMA and the thermoresponsive property of the PEO-b-PPO-b-
PEO central core.  The polymer with DNA remained water soluble below 23 oC, and 
upon heating to 37 oC reversible gelation occurred.  The release profile of the polyplexes, 
after gelation, did not go through an initial burst and remained linear between three and 
five days, depending on the initial formulation. 
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Figure 1.12.  Acrylamide monomer HPMA-DMAE  and analogues used in  hydrolysable 
polyacrylamide vectors 
 
Another acrylamide based polymer, poly(carbonic acid 2-dimethylamino-ethyl 
ester 1-methyl-2-(2-methacryloylamino)-ethyl ester) (PHPMA-DMAE), was developed 
by Funhoff et al. that incorporated hydrolysable grafts functionalized with tertiary amines 
(Figure 1.12).41  PHPMA-DMAE gave promising toxicity and transfection results in the 
absence of serum but had limited transfection efficiency while serum was present.  Luten 
et al. elaborated on this structure by synthesizing acrylamide monomer analogues of 
HPMA-DMAE to examine how subtle structural changes affected the rate of hydrolysis 
as well as serum dependence on transfection. (Figure 1.12).42  HPMA-DEAE, HPMA-
MPPM, and HPMA-BDMP showed less toxicity than poly(methacrylate) materials that 
did not contain a rapidly hydrolysable group, and transfection was serum independent. 
 
1.3 Degradable Delivery 
One tactic for improving synthetic delivery vehicles is increasing efficiency by 
incorporating different functionalities that take advantage of the natural machinery 
involved in the extracellular and intracellular delivery pathways.  The other tactic is to 
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decrease toxicity by either masking the cationic sites or by integrating biodegradable 
groups that leads to formation of less toxic oligomers.  Degradable sites can be installed 
in pendant functionality as seen in some of the examples already discussed but with only 
limited result in decreasing toxicity.  Alternatively, degradable groups can be placed on 
the main chain of the polymer.  Typically this has been done using poly(ester) or 
poly(amide) based materials.  The advantage of chain degradation is that the polymer can 
be fully digested as opposed to only pendant groups degrading, leaving the main chain 
intact.  The degradation products can be designed to be further metabolized by the body, 
or the starting monomers can be chosen from a range of biocompatible starting materials.  
Polymerization typically occurs via ring opening or step-growth polymerization.  The 
former generally yields high molecular weight polymers, and the latter lends itself to 
facile functionalization and access to large material libraries. 
 
 
 
Figure 1.13.  Conjugative addition polymerization to yield poly(β-amino ester)s utilizing bis-
secondary amines or primary amines 
 
1.3.1 Poly(β-amino ester)s 
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 The most studied poly(ester)s are poly(β-aminoester) materials.  The largest 
library of approximately 2300 materials was produced by Langer, and these were 
evaluated for toxicity and transfection ability with high throughput automated screening 
techniques (Figure 1.13).43  Polymerization occurred from conjugate addition of a 
primary amine or bis-secondary amine with a diacrylate.44  The majority of the vectors 
produced were inefficient at delivery due to issues of solubility, toxicity, and/or poor 
DNA complex formation.  Of the materials, 46 have shown promising delivery ability 
greater than PEI.  The best PBAEs were linear with molecular weights of ~10 kDa.  The 
top 9 materials contained a pendant hydroxyl group and the top three materials were 
synthesized with a hydroxyl functionalized alkyl amine and a hydrophobic 
dimethacrylate.  As seen in other systems, a material that has hydrophobic groups can 
enhance transfection due to an increase in membrane interactions, but at the same time, 
water solubility needs to be maintained.  It was also found that the end groups of the 
PBAEs were important.45  When the material was terminated with diemethacrylates, the 
DNA binding ability as well as transfection decreased.  When terminated with primary 
amines, DNA compaction as well as transfection was enhanced.  The best material was 
shown to have a 5-fold increase in efficiency compared to PEI with the hard to transfect 
HUVEC cell line and reached levels comparable to lentivirus and adenovirus delivery.  
This research demonstrated that small structural variations drastically alter bioactivity, 
and high throughput screening may serve as an essential tool in discovering materials that 
compete with viral delivery vectors. Despite the decrease in toxicity, the concentrations 
needed for delivery were much higher than the non-degradable systems, leaving an 
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opportunity to enhance cellular uptake and activity through new functionality and better 
controlled degradation.   
 
Figure 1.14.  Peptide based delivery vehicles; left: poly(L-Lysine); right: Oligo arginine R7 
 
1.3.2 Poly(amide)s 
 Poly(amide), peptide, and peptido mimetic materials have also been synthesized 
to take advantage of enzymatic degradation, while providing greater resistance to 
premature hydrolytic degradation.  The first poly(amide) used was poly(L-lysine) (PLL) 
which initially was a promising transfection agent.  PLL possessed some toxicity, and its 
efficiency has been far surpassed by other poly(amide) materials.  Chen et al. synthesized 
a series of copolymers of PLL with imidazoleacetic acid.46  Due to imidazole’s low pKa, 
the pendant group was designed to increase the buffering capability of PLL and 
ultimately enhance delivery.  It was found that the maximum activity was seen in lower 
molecular weight materials with higher imidazole incorporation.  Substitution of the 
primary amine functionality for imidazole decreased the toxicity of the material as well 
as increased the buffering capacity.  The transfection efficiency increased until an 
incorporation of 50% imidazole was reached.  Above this amount, the DNA 
complexation was not high enough for effective delivery.  
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Other functionalities have been used to enhance delivery.  One of the greatest 
adaptations that viral vectors possess is membrane-permeable peptides that enhance 
membrane association and uptake.47,48  A common characteristic of these peptides is a 
high concentration of cationic amino acids, most notably the guanidine containing 
arginine.  It has been proposed that the cationic domain (protein transduction domain, 
PTD) on these peptides interacts with heparin sulfate proteoglycans that promote cellular 
uptake. 47  To mimic the PTD oligo arginine peptides have been used as delivery vehicles 
or conjugated onto other delivery vehicles to enhance cellular uptake (Figure 1.14).49,50  
Utilizing the guanidine rich groups was shown to enhance delivery and oligos of around 7 
to 9 arginine repeat units were shown to be optimal. 
 
 
Figure 1.15. Polyamidoamine (PAMAM) synthesis; a): linear; b): dendritic 
 
One of the most studied classes of amido materials are poly(amido amine)s 
(PAMAM).  These materials have been synthesized in either linear or dendritic 
topologies (Figure 1.15).  Polymerization occurred by hydrogen transfer conjugate 
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addition to diacrylamides in an analogues synthesis to that of the PBAE materials.11  
Utilizing this modular synthetic approach, installation of a large range of functionalities, 
including more amino groups, carboxylic acids, alcohols, as well as peptides, was 
possible.  PAMAMs are less toxic than PLL, and including acids and alcohols further 
decreases their toxicity. 
 
 
 
Figure 1.16. Synthesis of a carboxylic acid and guanidine functionalized PAMAM designed as 
an RGD mimic 
 
Ferruti has developed linear PAMAM materials by reacting an acid functionalized 
diacrylate with agmatine (Figure 1.16).51-53  Agmatine is a decarboxylated analogue of 
arginine and contains a guanidinium group.  The repeat unit containing the acid and 
guanidine moiety mimics the cell active RGD sequence which promotes cellular uptake.  
In an acid base titration, three acid dissociation constants were observed, 2.25, 7.45, and 
≥12.1 from the carboxylic acid, tertiary amine, and guanidine, respectively.  The in vitro 
toxicity was lower than most amphiphilic PAMAM materials despite the excess cationic 
groups.  This was attributed to the RGD-like structure that behaved more like biologically 
active RGD than the typical cationic cell surface interactions.  The material in vivo was 
also found to be stealth-like without significant preferential accumulation in the liver, and 
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transfection efficiency was higher than other common PAMAMs and comparable to 
commercially available JetPEI. 
 
1.4 Biologically Derived Materials 
 
 
Figure 1.17.  Structure of the biologically derived chitosan 
 
1.4.1 Chitosan 
Biologically derived materials have also been studied to increase biocompatibility 
and provide a system that could be metabolized by the body.  Three main systems have 
been studied with the most prominent being chitosan.  Other materials have been 
synthesized incorporating β-cyclodextrin rings as well as non-degradable materials with 
conjugated biologically derived groups.  Chitosan delivery vehicles were produced by 
partial deacylation of chitin to afford glucosamine linked by glycosidic bonds (Figure 
1.17).54  Huang et al. have shown that delivery efficiency is highly dependent on 
molecular weight with 213 kDa yielding the highest activity in a range of materials (231 
– 17 kDa).55  This was attributed to more stable complex formation.  The optimum N/P 
ratio was 5,56 which was much more comparable to an optimum concentration for 
nondegradable polymers as opposed to typical degradable materials.  Modifications such 
as N-quaternization and incorporating imidazole bearing groups have been used to 
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increase efficiency.  Quaternization increased transfection efficiency while 
simultaneously increasing toxicity.  The imidazole moiety also increased transfection by 
increasing the buffering capacity, lending itself to endosomal release via the ‘proton 
sponge’ effect.57 
 
 
Figure 1.18.  Polymerization of β-cyclodextrin utilizing a cationic diamidine linkage 
 
1.4.2 β-cyclodextrin 
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Another carbohydate derivative, β-cyclodextrin (CD), have also been shown to 
increase biocompatibility and ultimately efficiency.  Synthesis of these polymers was 
achieved by stepgrowth polymerization between a diaminocyclodextrin and diimidate 
compounds (Figure 1.18).58  Transfection was optimized at an N/P ratio >10 with low 
toxicity.  The transfection was greatest when the linkage between CD segments was 6-8 
methylenes.  Greater than 8 methylenes diluted the charge density of the material 
resulting in solubility issues and low transfection efficiency.59  It was also found that 
these materials did not escape from the endosome via amine protonation, demonstrating 
that the transfection pathway is greatly dependent on the material being studied. 
 
 
 
Figure 1.19.  Linear PEI with sugar alcohol end groups 
 
1.4.3 Sugar alcohol functionalized 
To combine the high efficiency of non-degradable materials with the 
biocompatibility of naturally derived polymers, Rieneke studied the effect of 
incorporating reduced sugars onto effective delivery vehicles such as PEI (Figure 
1.19).60-63  This strategy greatly decreased toxicity compared to PEI.  Interestingly the 
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transfection efficiency was highly dependent on the stereochemistry of the carbohydrates.  
This was due to changes in the complex stability.  The toxicity was also shown to be 
dependent on the distance from the cationic site and the carbohydrate, with further 
separation resulting in increased toxicity. 
 
1.5 Bioactive Modifications 
 Further delivery enhancement has been achieved in the presence of targeting 
ligands, endosomolytic compounds, and nuclear localizing proteins.  A range of targeting 
ligands has been used such as RGD and folic acid where cellular uptake was initiated by 
receptor binding.6  The degree of specificity greatly depends on the ligand chosen.  For 
example the RGD receptor is present on many types of cells and little specificity is 
gained.  Other receptors, such as the folate receptor, are over expressed in some cell lines, 
and these systems have much higher specificity.  The effectiveness of targeting is greatly 
dependent on the chemistry involved in conjugation to the polymer, with the spacer 
between the targeting head group and the polymer being important, as well as the density 
of the ligation.3  It is critical for the site of conjugation between the polymer and ligand 
not to interfere with recognition or binding on the cell surface receptors. In polycationic 
materials there is also nonspecific binding via electrostatic interactions and specificity 
can only be attained when competition from nonspecific electrostatic interactions is 
minimized (charge neutrality). 
 Compounds that promote endosomal escape have also been shown to enhance 
transfection by a few orders of magnitude.  In in vitro studies chloroquin has become 
commonly added to take advantage of the buffering ability in the endosome.  This 
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approach however could not be used in vivo.3  Another strategy has been the conjugation 
of inactivated adenovirus particles.  Lastly, natural and synthetic fusogenic peptides have 
been attached to the delivery vehicle where upon acidification the proteins go through a 
structural transition.  These structural changes lead to membrane interaction and 
disruption, ultimately enhancing delivery efficiency from one to three orders of 
magnitude. 
 Once endosomal escape has been achieved there are many barriers present in the 
cytosol.  Diffusion of large molecules in the cytosol is extremely slow and inefficient.  
Techniques such as nuclear localizing proteins (NLP) are used to take advantage of the 
natural cell machinery and promote accumulation at the nucleus.3  Most NLPs are short 
cationic protein sequences, usually arginine or lysine rich.  The cationic nature of 
synthetic delivery vehicles are proposed to partially mimic NLPs, but with only limited 
efficiency.  Few complexes reach the nucleus, and little has been elucidated regarding the 
mechanism post endosomal release, to nuclear localization, and ultimately nuclear uptake 
and complex dissociation. 
 
6. Conclusions 
 Gene delivery is a dynamic process that manages many barriers in the 
extracellular and intracellular environment.  Materials are designed to address each of the 
steps in the delivery process, but in most cases optimizing one step in the delivery 
process interferes with another.  As seen in the characterization of PEI, the molecular 
weight, charge density, toxicity, buffering capacity, and DNA binding strength must be 
balanced to achieve optimal transfection.  These factors are greatly influenced by the 
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number, density, type, and pKa of the amines.  The transfection of b-PEI was enhanced 
by minimizing binding strength of the material by reducing charge density and number of 
primary and secondary amines.  This showed that the binding strength and buffering 
capacity of the material was greater than needed for transfection prior to acetylation, and 
the number of amines could be reduced to limit DNA binding strength without being 
detrimental to delivery.  On the other hand, l-PEI had lower buffering capacity and 
binding strength than b-PEI, and it was found that deacetylation of its amines enhanced 
delivery.  The molecular weight of vectors has also been shown to influence delivery.  
Typically, higher molecular weight materials were more efficient until a weight was 
reached where toxicity minimized the delivery enhancement.  To reduce toxicity, 
degradable and naturally derived materials have been used.  These vectors decrease 
toxicity, but the concentration needed for delivery is greatly increased with N/P ratios 
typically 20-70, as opposed to an N/P ratio of 5-10 for nondegradable materials.   
The balance between positive charge for complex formation and cell association 
with toxicity is one of the greatest obstacles in synthetic vectors.  Furthermore, 
maintaining a high buffering capacity is important for endosomal release.  If there is too 
much initial charge, complex formation and cell association will be strong but cell 
toxicity potentially increases.  Furthermore, if too many of the amines are protonated 
before cell internalization, there will be a limited ‘proton sponge’ effect, and the 
complexes will enter the cell but remain in the endosome and lysosome, eventually 
leading to degradation in the harsh environment.  If the binding strength is too strong the 
DNA will not dissociate and the genetic replication enzymes will be prevented from 
transcribing the genes.  If there are not enough cationic sites, however, there will be poor 
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complex formation and cell association, but also potentially lower toxicity.  With these 
parameters in competition there have been seemingly many contradictory examples in the 
literature and optimized properties for delivery to date has been material specific.  
Fundamental studies that isolate ionic charge, buffering, and binding strength would be 
advantageous to the field. 
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Chapter 2.  Using Ionization Control to Enhance Gene Delivery 
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Abstract.  The degree of ionization of amine containing polymers plays a critical role in 
gene delivery.  In order to develop new materials with optimized properties for 
transfection, a clear understanding of the influence of ionization needs to be established.  
We determined the influence of altering pKa values for structurally similar 
dialkylaminoisoprene polymers to balance the competing properties of complex 
formation and buffering capacity.  Free radical polymerization was used to generate 
materials with distinct pKa transitions.  The degree of ionization at physiological pH was 
determined and found to directly affect DNA binding, transfection efficiency, and 
toxicity.  It was shown that there is a balance between buffering capacity and complex 
formation with an ideal ionization in the range above 24% to below 50% amine 
protonation (pH = 7.4).  It was also found that a material with 33% protonation yielded a 
transfection efficiency (N/P ratio of 2) 100 fold higher than the field standard 
poly(ethyleneimine). 
 
1. Introduction 
A major focus of gene therapy research is the development of synthetic materials1-
13
 that aim to avoid the immunogenic or oncogenic14-18 effects encountered in viral 
delivery systems.  Despite a decrease in these health risks, synthetic delivery vehicles are 
generally less efficient than natural vehicles and usually have some degree of cell toxicity 
due to their cationic nature.19  However, synthetic polymers afford a high degree of 
control over their chemical composition, carrier size, and production.  To compete with 
the natural systems, synthetic polymers must efficiently 1) form a complex with DNA 
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(polyplex), 2) associate to the cell membrane and become internalized through 
endocytosis, 3) escape from the endosome, 4) transport the cargo to the nucleus, and 5) 
dissociate from the DNA.20  Most materials to date utilize 1o, 2o, and or 3o
 
amines, which 
at physiological conditions maintain protonated and unprotonated amines.  These 
properties are fundamental for complex formation and endosomal release, respectively.21   
During cell internalization, it is critical for the polyplex to escape from the 
endosome prior to fusion with a lysosome in order to avoid its harsh degradative 
environment.  The most prominent mechanism for escape is the ‘proton sponge’ effect 
proposed by Behr in 1995, which asserts upon endosomal acidification the neutral amines 
become protonated, followed by an influx of chloride ions to balance the charge.  
Ultimately, there is an increase in osmotic pressure and eventual membrane rupture.22-24  
From the early endocytic vesicle to the late endosome, the pH ranges from 7.4 to ~5.25  
Poly(ethyleneimine) (PEI) has become a standard in the field due to the material’s high 
delivery efficiency which is attributed to the range of amines that allow it to buffer over 
the entire lifetime of the endosome.  The result is efficient endosomal escape.24  Many of 
the reported materials attempt to mimic PEI’s buffering ability by integrating 
functionality, such as an imidazole moiety26-31, to impart varied pKa values and gain 
enhanced buffering characteristics.  
Previously, we reported a series of dialkylamino functionalized dienes that were 
shown to have higher transfection efficiency than PEI at low concentrations.10  Unlike the 
varied types of amines and broad buffering capability of PEI, these diene based materials 
contain only one type of tertiary amine, imparting a distinct buffering range.  With this in 
mind, it was not obvious why the aminodiene’s relative efficiency was high.  This 
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research focuses on the characterization of the buffering capability, DNA/polymer 
complex formation, and resulting transfection efficiency to further understand 
structure/biological activity relationships.  To this end, homopolymers and copolymers 
were synthesized with discrete pKa ranges to compare the effects of ionization on 
delivery efficiency.  Through this work insights will be gained into the effects of charge 
on transfection and property targets will be established for the design and screening of 
new gene delivery materials. 
 
2. Experimental Details 
2.1 Materials.  Plasmid DNA (pCMV-Luc) was purchased from Elim 
Biopharmaceuticals, Inc. (Hayward, CA).  Minimum essential medium (MEM), Hanks’ 
balanced salt solution (HBSS), Dulbecco’s phosphate buffered saline (PBS), fetal bovine 
serum (FBS), and a 1 kb DNA ladder were purchased from Invitrogen.  CellTiter 96 
AQueous one solution cell proliferation assay and luciferase assay system were 
purchased from Promega Corp. (Madison, WI).  BCA protein assay kit was purchased 
from Pierce (Rockford, IL).  Branched poly(ethyleneimine) with a molecular weight of 
25,000 g/mol was used as a control in the characterization experiments.  All other 
chemicals were purchased from Sigma-Aldrich and were used without further 
purification.   
2.2 Instrumentation.  1H and 13C NMR spectra were acquired in deuterated 
chloroform on a Bruker 400 AVANCE spectrometer.  Molecular weights were measured 
by a Waters GPC system using polystyrene standards.  The measurements were taken 
using 5% triethylamine/THF as the solvent on four columns (Waters Styragel HR0.5, 
39 
 
HR2, HR4, and HR5).  Glass transition temperatures were measured with a Seiko 220C 
differential scanning calorimeter, using a heating and cooling rate of 10 °C/min.  The 
glass transition temperatures were reported based on the second heating.  
Thermogravimetric analysis was carried out using a Perkin Elmer TGA 7 with a heating 
rate of 10 ºC/min in a N2 atmosphere.  Zeta potential measurements were completed on a 
Malvern Zeta Sizer Nano Series Nano-ZS instrument using Dispersion Technology 
Software version 4.20 at a wavelength of 633 nm using a 4.0 mW, solid state He-Ne laser 
at a scattering angle of 173 oC.  Cell culture plates were analyzed on a Molecular Devices 
SpectraMax M5.  Ethidium bromide stained agarose gels were visualized on a Bio Rad 
VersaDoc imaging system. 
2.3 Diene Synthesis.  General synthesis of 2-bromo-N,N-dialkylprop-2-en-1-
amine.  To a solution of N,N-dialkylamine in diethyl ether was added 2,3-
dibromopropene dropwise at 0 °C while stirring.  The reaction was allowed to warm to 
room temperature and to react for 18 h.  NaOH (1 M) was added until the formed salt 
dissolved, and the solution was extracted with diethyl ether (3x, 50 mL).  The organic 
layers were combined, washed with brine, dried with MgSO4, and concentrated.  The 
product was purified and isolated by distillation as a colorless liquid. 
2-bromo-N,N-dimethylprop-2-en-1-amine.  1H NMR (400 MHz, CDCl3): δ 5.77 
(s, 1H), 5.53 (s, 1H), 3.07 (s, 2H), 2.23 (s, 6H). 13C NMR (400 MHz, CDCl3): δ 131.60 
(CH2=CBrCH2), 119.12 (CH2=CBrCH2), 68.20 (CH2N), 45.14 (N(CH3)2) 
2-bromo-N,N-diethylprop-2-en-1-amine.  1H NMR (400 MHz, CDCl3): δ 5.90 (s, 
1H), 5.55 (s, 1H), 3.24 (s, 2H), 2.58 (q, 4H, J = 7.2 Hz), 1.03 (t, 6H, J = 7.2 Hz). 13C 
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NMR (400 MHz, CDCl3): δ 132.64 (CH2=CBrCH2), 116.80 (CH2=CBrCH2), 61.46 
(CH2N), 46.67 [N(CH2CH3)2], 11.73 [N(CH2CH3)2] 
2-bromo-N,N-dipropylprop-2-en-1-amine.  1H NMR (400 MHz, CDCl3): δ 5.90 
(s, 1H), 5.53 (s, 1H), 3.23 (s, 2H), 2.43 (t, 4H, J = 7.6), 1.45 (m, 4H, J = 7.6), 0.88 (t, 6H, 
J = 7.2). 13C NMR (400 MHz, CDCl3): δ 133.60 (CH2=CBrCH2), 117.80 (CH2=CBrCH2), 
63.00 (CH2N), 55.92 [N(CH2CH2CH3)2], 20.78 [N(CH2CH2CH3)2], 12.16 
[N(CH2CH2CH3)2] 
General synthesis of 2-(N,N-diakylaminomethyl)-1,3-butadiene.  To a flame dried 
1 L three neck flask was added [1,3-bis(diphenylphosphino)propane]dichloronickel (0.5 
mol%), dialkylaminobromopropene, and dry THF under a N2 atmosphere.  Vinyl 
magnesium bromide (1 M in THF) was added dropwise at 0 °C while stirring.  The 
reaction was allowed to warm to room temperature and to react for 24 h.  The reaction 
was quenched with NH4Cl (satd.) and extracted with diethyl ether (3x, 50 mL).  The 
organic layers were combined, washed with brine, dried with MgSO4, and concentrated.  
The product was purified and isolated by distillation as a colorless liquid. 
N,N-dimethyl-2-methylenebut-3-en-1-amine (Dimethylaminoisoprene; DMAI).  1H 
NMR (400 MHz, CDCl3): δ 6.36 (dd, 1H, J1 = 17.6 Hz, J2 = 11.2 Hz), 5.41 (d, 1H, J = 
17.6), 5.14 (s, 1H), 5.11 (m, 1.5H), 5.09 (s, 0.5H), 3.01 (s, 1H), 2.21 (s, 1H). 13C NMR 
(400 MHz, CDCl3): δ 143.31 (CH2=CCH2N), 137.56 (CH2=CHCCH2N), 117.73 
(CH2=CHCCH2N), 114.44 (CH2=CCH2N), 61.86 (CH2N), 45.54 [N(CH3)2] 
N,N-diethyl-2-methylenebut-3-en-1-amine (Diethylaminoisoprene; DEAI).  1H 
NMR (400 MHz, CDCl3): δ 6.39 (dd, 1H, J1 = 17.6 Hz, J2 = 10.8 Hz), 5.46 (d, 1H, J = 
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17.6), 5.204 (s, 1H), 5.142 (s, 1H), 5.08 (d, 1H), 3.16 (s, 1H), 2.51 (q, 4H, J = 7.2), 1.02 
(t, 6H, J = 7.2). 13C NMR (400 MHz, CDCl3): δ 144.07 (CH2=CCH2N), 137.92 
(CH2=CHCCH2N), 116.98 (CH2=CHCCH2N), 113.96 (CH2=CCH2N), 55.25 (CH2N), 
47.03 [N(CH2CH3)2], 11.67 [N(CH2CH3)2] 
N,N-dipropyl-2-methylenebut-3-en-1-amine (Dipropylaminoisoprene; DPAI).  1H 
NMR (400 MHz, CDCl3): δ  6.38 (dd, 1H, J1 = 17.6 Hz, J2 = 10.8 Hz), 5.45 (d, 1H, J = 
17.6), 5.22 (s, 1H), 5.12 (s, 1H), 5.06 (d, 1H, J = 10.8), 3.15 (s, 1H), 2.35 (t,4H, J = 7.6 
Hz), 1.46 (m, 4H, J = 7.6 Hz), 0.87 (t, 6H, J = 7.6). 13C NMR (400 MHz, CDCl3): δ 
144.22 (CH2=CCH2N), 137.94 (CH2=CHCCH2N), 116.99 (CH2=CHCCH2N), 113.92 
(CH2=CCH2N), 56.66 (CH2N), 56.22 [N(CH2CH2CH3)2], 20.18 [N(CH2CH2CH3)2], 
11.95 [N(CH2CH2CH3)2] 
2.4 Polymer Synthesis.  Free Radical Polymerization of 2-(N,N-
dialkylaminomethyl)-1,3-butadiene.   Monomer and AIBN were added to an ampoule 
with a magnetic stir bar. After three freeze-pump-thaw cycles, the ampoule was sealed 
under nitrogen and placed in an oil bath preheated to 70 °C.  After 24 h, the polymer was 
precipitated into acetone at -78 °C and dried under vacuum at room temperature for 5 d.  
poly(2-(N,N-dimethylaminomethyl)-1,3-butadiene) (PMAI).  1H NMR (400 MHz, 
CDCl3): δ 5.26 (s, 1H), 2.83 and 2.74 (s, 2H from trans and cis CH2N, respectively), 2.13 
[broad, 10H, 6 from 2(CH3) and 4 from the polymer backbone]. 13C NMR (400 MHz, 
CDCl3): δ 136.99 (CH2CH=CCH2), 128.36 (CH2CH=CCH2), 66.52 [CH2N(CH3)2, cis], 
58.37 [CH2N(CH3)2, trans], 45.40 [N(CH3)2], 35.80 (CH2CH=CCH2), trans), 28.75 
(CH2CH=CCH2, cis), 26.51 (CH2CH=CCH2) 
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poly(2-(N,N-diethylaminomethyl)-1,3-butadiene) (PEAI).  1H NMR (400 MHz, 
CDCl3): δ 5.27 (s, 1H), 2.92 (s, 2H, trans), 2.85 (s, 2H, cis), 2.41 (m, 4H), 2.10 (m, 4H), 
0.96 (m, 6H). 13C NMR (400 MHz, CDCl3): δ 137.57 (CH2CH=CCH2), 127.72 
(CH2CH=CCH2), 59.94 [CH2N(CH2CH3)2, cis], 51.84 [CH2N(CH2CH3)2, trans], 46.43 
[N(CH2CH3)2], 36.13 (CH2CH=CCH2), trans), 27.97 (CH2CH=CCH2, cis), 26.61 
(CH2CH=CCH2), 11.67 [N(CH2CH3)2] 
poly(2-(N,N-dipropylaminomethyl)-1,3-butadiene (PPAI)).  1H NMR (400 MHz, 
CDCl3): δ 5.28 (s, 1H), 2.93 (s, 2H, trans), 2.85 (s, 2H, cis), 2.27 (m, 4H), 2.12 (m, 4H), 
1.42 (m, 4H), 0.85 (m, 6H). 13C NMR (400 MHz, CDCl3): δ 138.00 (CH2CH=CCH2), 
127.80 (CH2CH=CCH2), 61.29 [CH2N(CH2CH2CH3)2, cis], 55.65 [N(CH2CH2CH3)2], 
53.09 [CH2N(CH2CH2CH3)2, trans], 36.02 (CH2CH=CCH2, trans), 28.04 
(CH2CH=CCH2, cis), 26.42 (CH2CH=CCH2), 20.21 [N(CH2CH2CH3)2], 12.04 
[N(CH2CH2CH3)2] 
Free Radical Copolymerization.  The density for each monomer was determined, 
and varied amounts of monomer were added via micropipette to an ampoule with a 
magnetic stir bar.  After three freeze-pump-thaw cycles, the ampoule was sealed under 
nitrogen and placed in an oil bath preheated to 70 °C.  After 24 h, the polymer was 
precipitated into acetone at -78 °C and dried under vacuum at room temperature for 5 d.  
poly(2-(N,N-dimethylaminomethyl)-3-methyl-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-3-methyl-1,3-butadiene) (MePr)
.  
1H NMR (400 MHz, CDCl3): δ 
5.28 (s, 1H), 2.94-2.74 (m, 2H), 2.26 (broad, 4H), 2.14 [m, 10H, 6 from 2(CH3) and 4 
from the polymer backbone], 1.42 (broad, 4H), 0.84 (broad, 6H). 13C NMR (400 MHz, 
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CDCl3): δ 137.10 (CH2CH=CCH2), 128.25 (CH2CH=CCH2), 66.53 [CH2N(CH3)2, cis], 
61.21 [CH2N(CH2CH2CH3)2, cis], 58.23 [CH2N(CH3)2, trans], 55.73 [N(CH2CH2CH3)2], 
53.04 [CH2N(CH2CH2CH3)2, trans], 45.77 [N(CH3)2], 35.91 (CH2CH=CCH2, dimethyl, 
trans), 34.56 (CH2CH=CCH2, dipropyl, trans), 29.09 (CH2CH=CCH2, dimethyl, cis), 
28.81 (CH2CH=CCH2, dipropyl, cis), 27.98 (CH2CH=CCH2, dimethyl), 26.39 
(CH2CH=CCH2, dipropyl), 20.23 [N(CH2CH2CH3)2], 12.04 [N(CH2CH2CH3)2] 
poly(2-(N,N-diethylaminomethyl)-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-1,3-butadiene) (EtPr).  1H NMR (400 MHz, CDCl3): δ 5.28 (s, 
1H), 2.94-2.88 (m, 2H), 2.42 (broad, 4H), 2.26 (broad, 4H), 2.11 (broad, 4), 1.43 (broad, 
4H), 0.978 (broad, 6H), 0.85 (broad, 6H). 13C NMR (400 MHz, CDCl3): δ 137.90 
(CH2CH=CCH2), 127.61 (CH2CH=CCH2), 61.23 [CH2N(CH2CH2CH3)2, cis], 60.16 
[CH2N(CH2CH3)2, cis], 55.73 [N(CH2CH2CH3)2], 53.04 [CH2N(CH2CH2CH3)2, trans], 
51.92 [CH2N(CH2CH3)2, cis], 46.95 [N(CH2CH3)2], 34.60 (CH2CH=CCH2, diethyl, 
trans), 34.62 (CH2CH=CCH2, dipropyl, trans), 29.21 (CH2CH=CCH2, diethyl, cis), 28.85 
(CH2CH=CCH2, dipropyl, cis), 28.04 (CH2CH=CCH2, diethyl), 26.50 (CH2CH=CCH2, 
dipropyl), 20.24 [N(CH2CH2CH3)2], 12.00 [N(CH2CH3)2], 11.72 [N(CH2CH2CH3)2] 
Reactivity Ratios.  Reactivity ratios were determined by 1H NMR with low 
conversion (< 10%) copolymerizations of DMAI and DPAI.  The polymerization setup 
was identical to the copolymer procedure.  Reactions were run for 2 h and samples were 
added directly to NMR tubes containing CDCl3. 
 2.5. Polymer/Polyplex Characterization.  pH Titration.  The pH of the solution 
was monitored using a Pasco pH meter calibrated with 4.0 and 10.0 buffers and verified 
with a 7.4 phosphate buffer.  Polymer solutions were made by dissolving approximately 
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20 mg of material into 10 mL of 0.1 M HCl.  The solution was titrated with 0.1 M NaOH, 
and the pH was recorded after equilibration (30 s).  A derivative of the curve was used to 
determine the acid base equilibrium points.  A line of best fit was taken through the 
buffering plateau, and the average of the two equilibrium points was used to determine 
the inflection point of the titration curve. 
Standard Polyplex Formation.  To 1 mg of each polymer sample was added 15 
µL of glacial acetic acid followed by 485 µL of either opti-MEM or MEM media to make 
polymer solutions at a concentration of 2 mg/mL.  Once dissolved the polymer samples 
were diluted with the appropriate media to obtain the polymer solutions at concentrations 
of 0.1 mg/mL.  To solutions of 2 µg/mL pCMV-Luc plasmid in media was added the 
polymer solution and media to form complexes at desired N/P ratios with total volumes 
of 200 µL. 
Agarose Gel Electrophoresis.  The standard polyplex formation was used to 
generate complexes at desired N/P ratios.  Electrophoresis was conducted on a 0.75% 
agarose gel in TAE buffer containing 0.5% ethidium bromide for 45 min. at 120 V.  The 
bands were visualized using ethidium bromide staining.  
Cytotoxicity Assay.   HeLa cells were grown in 96-well plates at a density of 
5×103 cells/well in 150 µL of growth medium (89% MEM, 10% FBS, 1% L-glutamine).  
Cells were grown for 24 h.  The media was removed, and the cells were washed with 100 
µL of DPBS and incubated with 15 µL of polyplex solution and 135 µL of MEM for 4 h.  
The solutions were removed, and the cells were washed with DPBS.  Following the 
addition of 150 µL of MEM, the cells were allowed to recover for 20 h.  The solutions 
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were removed, and the cells were washed with DPBS.  To the cells were added 100 µL of 
MEM and 20 µL of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazoleum, inner salt (MTS, from CellTiter 96 AQueous One Solution 
Cell Proliferation Assay kit).  The cells were incubated for 4 h and the absorbance at 490 
nm was monitored on a Molecular Devices SpectraMax M5 plate reader.    
Transfection Efficiency Assay.  HeLa cells were grown in 48-well plates at a 
density of 1.5×104 cells/well in 300 µL of growth medium (89% MEM, 10% FBS, 1% L-
glutamine).  Cells were grown for 24 h.  The media was removed, and the cells were 
washed with 300 µL of HBSS and incubated with 450 µL of opti-MEM and 50 µL of 
polyplex solution for 4 h.  The solutions were removed, and the cells were washed with 
HBSS and incubated with 500 µL of opti-MEM (89% MEM, 10% FBS, 1% L-glutamine) 
for 32 h.  The growth medium was removed and the cells were washed with 300 µL of 
HBSS and treated with 150 µL of cell lysis buffer (1X).  The resulting mixtures were 
centrifuged and 20 µL of supernatant were added directly to white opaque 96-well plates.  
Luciferase activity was quantified by adding 100 µL of luciferase assay reagent, followed 
by a 2 second delay.  Luminescence was quantified over a 1 second read time.  The result 
was normalized to the total protein content using a BCA protein assay whose absorption 
was monitored at 562 nm on a Molecular Devices SpectraMax M5 plate reader. 
Zeta Potential Measurements.  Plasmid solutions were made by diluting 80 µL of 
pCMV-Luc (1 mg/mL) with 9.92 mL of 100 mM HEPES buffer to give a final DNA 
concentration of 8 µg/mL.  Polymer solutions were made by dissolving 1 mg of material 
with 15 µL of glacial acetic acid and 9.985 mL of 100 mM HEPES buffer.  The final pH 
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of the polymer was verified to be 7.4.  Using an autotitrator, the polymer concentration 
was increased by an N/P ratio of 0.25 up to a total ratio of 10, and the ζ-potentials were 
monitored. 
 
3. Results and Discussion 
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Scheme 2.1.   Synthesis of dialkylaminoisoprenes and resulting polymers; a MePr-X (X = percent 
DMAI); b EtPr-Y (Y = percent DEAI) 
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Table 2.1. Radical Homo- and Copolymerizations of DMAI, DEAI, and DPAI 
Sample Feed
a
 
(%) 
Actual 
Incorp.b 
(%) 
‹Mn›c 
(× 10-3 g/mol) PDI
c
 
Tgd 
(°C) 
Decompositione 
(oC) 
5%        10% 
DPf 
PMAI - - 16 1.50 -29 353 365 109 
PEAI - - 15 2.29 -46 337 359 120 
PPAI - - 20 1.67 -55 313 352 122 
MePr-20 20 17 19 1.59 -46 354 366 117 
MePr-40 40 44 17 1.66 -47 330 358 125 
MePr-54g 54 54 17 1.74 -44 345 362 140 
MePr-60 60 59 19 1.77 -38 345 361 136 
MePr-80 80 80 17 1.63 -35 344 362 118 
EtPr-20 20 19 19 1.82 -54 316 353 127 
EtPr-40 40 38 20 1.92 -47 350 364 117 
EtPr-60 60 58 18 2.15 -46 346 360 114 
EtPr-80 80 78 17 2.50 -46 345 360 109 
a  amine monomer  relative to the DPAI; b determined by 1H NMR; c determined by GPC; d 
determined by DSC; e determined by TGA; f based on the average MW of the monomers 
incorporated into the polymer; g designed as a pKa mimic of PEAI 
 
3.1 Synthesis 
The monomers, dimethylaminoisoprene (DMAI), diethylaminoisoprene (DEAI), 
and dipropylaminoisoprene (DPAI) were synthesized (Scheme 2.1) in high purity as 
previously described.32  Poly(dimethylaminoisoprene) (PMAI), 
poly(diethylaminoisoprene) (PEAI), and poly(dipropylaminoisoprene) (PPAI) 
homopolymers with molecular weights of 16.0, 15.2, 20.4 kg/mol and polydispersities 
(PDIs) of 1.50, 2.29, 1.67, respectively, were synthesized using AIBN at 70 oC for 24 h.  
The molecular weights of the copolymers ranged from 16 to 20 kg/mol with high fidelity 
between the feed and actual monomer incorporation.  All of the polymers were 
comparable molecular weight and PDI to the materials previously synthesized in our 
group for gene delivery studies.10  For each of the materials, there was one glass 
transition indicating formation of random copolymers (Table 2.1).   
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To further verify random copolymer formation, the reactivities of DMAI and 
DPAI monomers were determined by 1H NMR (Table 2.2).33  Monomer concentrations 
were varied by 0.1 equivalent of DMAI relative to DPAI.  The ratio of monomers was 
determined by normalizing the region of 2.8 to 3.2 ppm for the methylenes extending 
from the diene or polymer backbone and integrating the peaks at 3.13 and 3.01 ppm, 
which correspond to DMAI and DPAI, respectively.  The normalized monomer 
concentration ( tA ) at time t and the starting monomer concentration ( 0A ) were used to 
determine the mole fraction of DMAI ( MtF ) and DPAI ( PtF ) incorporated into the 
copolymers (equations 1 and 2; Table 2.2). 
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Table 2.2. Calculated values for DMAI and DPAI reactivity ratio determination 
 
 
M
tA
*
 
P
tA
*
 
M
tF  
P
tF  
Conv.* 
(%) F  f  G  H  
MePr-10 0.15 1.52 0.15 0.85 8.5 0.18 0.11 -0.51 0.07 
MePr-20 0.31 1.37 0.28 0.72 7.5 0.39 0.25 -0.38 0.16 
MePr-30 0.48 1.20 0.37 0.62 8.5 0.60 0.43 -0.28 0.31 
MePr-40 0.67 1.05 0.46 0.54 7.5 0.87 0.67 -0.10 0.51 
MePr-50 0.86 0.86 0.50 0.50 8.5 1.00 1.00 0.00 1.00 
MePr-60 1.06 0.70 0.58 0.42 6.0 1.40 1.50 0.43 1.61 
MePr-70 1.25 0.52 0.65 0.35 7.5 1.87 2.33 1.09 2.90 
MePr-80 1.46 0.35 0.74 0.26 5.5 2.80 4.00 2.57 5.71 
MePr-90 1.67 0.18 0.87 0.13 5.5 6.50 9.00 7.62 12.46 
*
 Determined by 1H NMR 
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Copolymer incorporation ratios ( F ) and monomer feed ratios ( f ) were then determined 
using the following equations: 
 
P
t
M
t
F
F
F =       (3)  P
M
A
Af
0
0=       (4) 
 
The value of F  and f  were used to determine G  and H  (Finemann-Ross method; 
equations 5 and 6; Table 2.2). 
 
)(F
F
fG 1−=       (5)     
F
fH
2
=       (6)  pm rHrG −=       (7) 
 
A plot of equation 7 gave the ratios for DMAI ( mr = 0.64) and for DPAI ( pr = 0.60).  This, 
in addition to thermal data, indicated the generation of random copolymers.  The 
structural similarities of DEAI and DPAI prevented accurate reactivity ratios from being 
determined, but due to the high incorporation fidelity and single glass transition, it is 
believed that these materials are also random copolymers. 
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3.2 Ionization Studies 
It is thought that the range of amines or pKa values contained in PEI results in 
efficient buffering at various pH values, and this property leads to high transfection 
efficiency.34  Previously, we have seen high efficiency in a diene based material that 
contains one unique tertiary amine.  This finding deviates from the ideology that varied 
pKa values lead to higher transfection efficiency.  Given that a broad buffering capacity 
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Figure 2.1  Acid/base titrations for the (a) MePr and (b) EtPr series 
a) 
b) 
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range is not required, the question remains, what are the optimum buffering properties 
that lead to high transfection efficiency? 
 
 
 
To examine buffering capacity and ionization, acid-base titrations were carried 
out to determine the average pKa of the series of aminoisoprene homopolymers in 
solution and to compare their buffering profiles with the profile for PEI (Figure 2.1).  The 
titration experiments began with dissolution of ~20 mg of material in 10 mL of 0.1 N 
HCl and slowly titrating the solution with 0.1 N NaOH.  The acid/base equilibrium points 
were then used to determine the inflection point of the curve, giving pKa values for 
PMAI, PEAI, and PPAI of 7.9, 6.9, and 5.8, respectively.  One of the first observations 
that came from the initial experiments was the small difference of pH between the onset 
and endpoint of amine protonation.  A more drastic change in pH was expected due to the 
electrostatic depression of amine protonation as the number of charged sites increased.  
The result of the titration gave an almost distinct buffering transition for each material, 
y = 2.0529x + 5.8286
R² = 0.9983
y = 1.09x + 5.8833
R² = 0.9758
5
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Figure 2.2. pKa as a function of monomer feed; (♦) EtPr series and (■) MePr 
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and the mechanism for which is under further investigation.  These titration results (Table 
2.3) help to better understand the results of our previous work where it was determined 
that PMAI and PPAI had low transfection efficiency, but PEAI showed higher efficiency 
than PEI at an N/P ratio of 2 (N/P ratio = protonizable amines of the polymer to 
phosphates of the DNA).35  Polyplex formation for PMAI was the most efficient in the 
series with moderate to low transfection efficiency.  With an average pKa of 7.9, PMAI 
had 76% of its amines protonated at physiological pH, explaining the low concentration 
needed for complex formation.  As such, this left only a small percentage of free amines 
available for endosomal buffering and release.    On the other hand, PPAI had 2.4% of its 
amines protonated, and it was shown to be an ineffective DNA binder at concentrations 
below an N/P of 20.  PEAI, with a pKa of 6.9, had 24% of its amines protonated and 
offered the best balance of charge for polyplex formation and buffering for endosomal 
release.  Similar observations have been made by Ahmad et al. where they observed a  
 
 
 
 
 
 
 
 
 
Table 2.3. Acid/base titrations and 
polyplex characterization 
Polymer pKa 
Ionization 
pH = 7.4 
(%) 
PMAI 7.9 76 
PEAI 6.9 24 
PPAI 5.8  2.4 
MePr-20 6.3  7.4 
MePr-40 6.7 16 
MePr-54 6.9 24 
MePr-60 7.1 33 
MePr-80 7.4 50 
EtPr-20 6.2  5.9 
EtPr-40 6.3  7.4 
EtPr-60 6.6 14 
EtPr-80 6.8 20 
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bell-shaped curve that defined the relationship of charge density and transfection 
efficiency in a series of liposomes.36  Our data agree with their observation that there is a 
region that balances buffering capacity and complex stability to optimize transfection. 
With this understanding, we wanted to further define an optimal window of 
ionization that balances the competing properties of charge and buffering potential.  To 
answer this question, copolymers (PMAI-co-PPAI and PEAI-co-PPAI) were designed 
with varying ratios of monomer incorporation, shifting the pKa, and thereby percent 
ionization, to access pKa values above and below 6.9 (PEAI; 24% ionization).  The feed 
ratios were varied by 20% up to homopolymers.  Similar to the homopolymers, titration 
experiments revealed a single distinct transition
 
for each copolymer (Figure 2.1), and the 
resulting values had a linear relationship with regard to the monomer feed (Figure 2.2).  
A line of best fit in a plot of pKa as a function of feed afforded an equation that can be 
used to synthesize a material with a programmed pKa between 5.8 and 7.9.  To take 
advantage of this tool the material MePr-54 was designed with a target pKa of 6.9 to 
directly compare with the ionization of PEAI.  In doing so, the structural differences 
between these two materials are separated from the charge, giving a more accurate 
assessment of ionization and structure on overall transfection efficiency.  To further 
investigate the properties of these materials in reference to charge, DNA binding agarose 
gels and transfection experiments were conducted.  
 
3.3 DNA Binding Agarose Gels and Transfection 
DNA binding ability was investigated using agarose gel electrophoresis to 
determine the polymer concentrations that each material could effectively bind DNA 
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(Figure 2.3).  Transfection efficiency (Figure 2.4) was also evaluated and then related to 
ionization/buffering and complex formation to establish a target for material design.  In 
the DNA binding experiments complexes were formed at various N/P ratios (0.1 – 100; 
depending on the charge neutralization).  For the transfection experiments, a 6000 base 
pair pCMV-luc plasmid containing the luciferase reporter gene was used, and each 
material was tested at N/P ratios of 2, 4, and 10.   
At an ionization of 76%, PMAI was shown to have efficient complex formation 
with quenching at an N/P ratio of 1.  Meanwhile, it had low buffering capacity and only 
nominal transfection, which may be from the inability of the material to serve as an 
efficient ‘proton sponge’.  PPAI, on the other hand, with an ionization of 2.4% had poor 
complex formation with quenching at an N/P of 20, but simultaneously maintained high 
buffering capacity.  With the inability to form a neutral complex until high polymer 
concentrations, this material had poor transfection efficiency.  When looking at the MePr 
copolymer series, the percent ionization was shifted to examine whether a balance 
between complex formation and buffering capacity could be reached.  In this series, as 
the DMAI incorporation decreased the complexation efficiency decreased.  Much like 
PPAI, MePr-40 (16.6% ionization) and MePr-20 (7.6% ionization) possessed high 
buffering capacity, but had the lowest binding ability, with complexation occurring above 
an N/P of 4.  These materials showed low transfection, with the exception of MePr-40 
which had some efficiency at an N/P of 10.  MePr-80 and MePr-60 had ionizations of 50 
and 33%, respectively, and showed DNA binding near an N/P ratio of 2.  These materials 
had drastically improved transfection at this low polymer concentration, with the 
efficiencies 100 fold higher than any of the diene homopolymers or PEI.  MePr-60 was 
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the highest performing polymer in this study, and with 33% ionization, balances complex 
formation with strong buffering ability.   
PEAI was less efficient at DNA binding than PMAI with quenching at an N/P 
ratio of 2, and similarly, the complexation efficiency in the EtPr series decreased as 
DEAI incorporation decreased.  PEAI, with ionization of 24%, showed transfection 
twenty fold higher than plasmid DNA at an N/P ratio of 4, but at an N/P of 2 and 10 there 
was low efficiency.  On the other hand, EtPr-80, with an ionization of 20%, had low 
efficiency until an N/P of 10.  This followed the same trend as the MePr series where the 
materials below 16% ionization did not effectively complex the DNA until an N/P of 10 
or greater and also showed no transfection ability at the lower concentrations tested.  
Based on these results it appears that a window above 24% and below 50% charge 
optimizes the balance between complex formation and buffering capacity and is a 
reasonable target for designing materials that transfect at low polymer concentrations. 
MePr-54 was designed to mimic the pKa of PEAI which was 6.9.  PEAI had more 
efficient binding than its analogue, MePr-54, despite having the same degree of 
ionization.  The transfection efficiency however, for MePr-54 and PEAI were similar 
with only small variations in efficiency at low concentrations.  At an N/P of 10, MePr-54 
maintained higher transfection efficiency than PEAI which is possibly the result of 
requiring slightly higher concentrations to form a neutral complex with DNA.  Despite 
having an identical charge and buffering capacity, the structural property of the material 
played an important role, and the design of future materials will probe the influence of 
binding affinity on transfection; taking into account contributions from electrostatic, 
steric, hydrophobic, hydrogen bonding, and van der Waals interactions. 
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Figure 2.3. Agarose gel electrophoresis assay; Lanes correspond to various N/P ratios; 
Lane L: DNA molecular ladder; lane P: Naked DNA; All other lanes correspond to 
various N/P ratios; a) MePr series and b) EtPr series 
 
a) 
b) 
 Figure 2.4. Transfection experiments of selected materials with HeLa cells at N/P ratios 
of 2,4, and 10; Values represe
 
3.4 Complex Studies
The polyplexes were also characterized by surface charge measurements (
potential; Appendix A).  For nonspecific 
maintain a positive surface charge to interact with
revealed that the surface charge of the complexes closely followed the pK
materials and transfection only occurred at concentrations for each material that resulted 
in positive surface charge; however, 
than the percent ionization would have predicted.  This shows that the effective charge is 
not only governed by the pKa
binding which results in further protonation of the amines.  It was previously reported 
that binding can induce proton 
1
10
100
1000
10000
100000
1000000
10000000
2
lo
g(R
LU
/ µµ µµ
g 
pr
o
te
in
)
57 
nt mean + SD (n = 3) 
 
transfection, it is important for the complex to 
 the cell surface.  The zeta potential 
a
the isoelectric point occurred at lower concentrations 
 of the materials but also that there is a cooperative effect of 
transfer from the surrounding media.  This occurs from a 
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Figure 2.5. Cytotoxicity of polyplexes 
 
3.5 Cytotoxicity 
The in vitro cytotoxicity was then evaluated using an MTS assay (
The polyplexes were tested at N/P ratios ranging from 1 to 100 with a DNA 
concentration of 0.5 µg/mL.  PPAI was shown to have the lowest toxicity followed by the 
copolymers with higher incorporation of DPAI.  The DEAI series also showed less 
toxicity when compared to the DMAI series.  As expected, the materials with the highest 
charge density had the highest toxicity potentially stemming from membrane perturbation 
of the cell.19,39,40 However, the toxicity of PEAI was slig
PEAI was also slightly more efficient at complexation
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from the incorporation of the dipropylamine that may decrease surface interactions 
compared to the diethylamine functionality. 
 
4. Conclusions 
A series of tertiary amine functionalized homopolymers and copolymers have 
been synthesized with high control over their ionization potential.  A combination of the 
buffering capacity as well as binding affinity governs the transfection efficiency of these 
diene based delivery vehicles.  We have shown that delivery is possible with materials 
that have distinct buffering ranges as opposed to the broad range that occurs with PEI.  
MePr-60 maintains 33% amine protonation at a pH of 7.4, whereas PEI has only 20% 
protonation.22  This enabled MePr-60 to form a complex at low concentrations while 
maintaining a high buffering capacity.  Ultimately, this led to the ability of MePr-60 to 
transfect at a concentration (N/P of 2) that PEI was not able.  In this study a window from 
24% to 50% ionization was found to be optimal for transfection with the best material 
having 33% amine protonation.  This range may serve as a target for designing future 
delivery systems. While the facile acid/base titration proved useful as an initial test, based 
on the differences between PEAI and MePr-54 continued work is needed to examine the 
ionization properties of these materials in an environment that better mimics that of the 
endosome.  To this end, more sophisticated titration experiments have been developed41 
and will be utilized for further biophysical characterization. Future studies will also focus 
on quantifying DNA binding affinity in order to identify a desired binding strength, 
determine the contribution of various forces involved in complex formation, and 
ultimately further establish a guideline in the design of new materials. 
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Chapter 3.  Synthesis of Degradable Gene Therapy Materials with 
Decreased Toxicity 
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Abstract.  A series of amine functionalized polyesters were synthesized to examine the 
influence of a degradable scaffold on cytotoxicity.  To achieve high amine density, a new 
monomer, 4-((diethylamino)methyl)-5-methylcyclohex-4-ene-1,2-dicarboxylic acid, was 
designed to avoid unwanted crosslinking found in materials previously developed by our 
group.  Polymerization of this monomer was successful, and amine homopolymers as 
well as copolymers were produced.  The resulting materials were then evaluated for their 
toxicity, DNA binding, and transfection efficiency.  The toxicity was found to be much 
less than an industry standard, poly(ethyleneimine), but transfection efficiency was 
nominal even at elevated concentrations. 
 
1. Introduction 
 Despite the advantages of synthetic gene delivery materials, one of the most 
pervasive and limiting properties is cytotoxicity.1-6  This in part stems from the cationic 
nature of materials that ultimately induces membrane perturbation upon cell association 
and leads to death.  To minimize these effects, two main strategies have been employed.  
The first is to shield the charge by incorporating biocompatible hydrophilic groups such 
as ether blocks, grafts, or main chain segments.7-9  As in other areas of biomedical 
research, creating poly(ethylene glycol) (PEG) blocks and grafts (often referred to as 
pegylation) leads to micelle formation that reduces nonspecific cell interactions.10,11  
Upon DNA complexation, electrostatic neutralization results in hydrophobic aggregation 
of the polycation/DNA complex, and these aggregates are stabilized by the hydrophilic 
PEG chains extending into the aqueous environment.  This shielding enables the 
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complexes to avoid premature clearance from the immune or RES systems, yielding long 
blood circulation times.  The decrease in toxicity is from a reduction of cell interactions, 
but unfortunately this also prevents uptake at the target site, and low delivery efficiency 
is common. 
Another shielding strategy has been incorporating electronegative or anionic 
groups onto grafts or the main chain of the polymer.12-14  Alcohol or carboxylic acid 
functionalized materials have shown great promise in reducing toxicity without being 
detrimental to the bioactivity.  However, the concentration (N/P ratio; number of amines 
of the polymer divided by the number of phosphates on the DNA) needed to reach 
competitive transfection efficiency with the nonshielded systems was much higher, 
typically well above an N/P ratio of 20.  The functional groups also impose limitations on 
the synthesis of the materials mandating mild reaction conditions and/or the use of 
protecting groups.  These materials were also sensitive to the proximity of the shielding 
group from the amine, with a shorter distance being more effective at decreasing toxicity.  
This can lead to limitations in the design and synthesis of materials. 
The second strategy for decreasing toxicity has been to integrate the cationic 
functionality onto a degradable scaffold.15  Degradation can be a result of bioreduction 
(disulfides)16,17, enzymatic degradation (amides, carbohydrates)14,18-24, or hydrolytic 
degradation (acetals, carbonates, esters)3,12,13,25.  Generally degradable systems, not 
unlike those with charge shielding, have decreased toxicity, but also require higher N/P 
ratios to compete with the nondegradable systems.  This is more pronounced in materials 
with more labile functionalities such as the poly(esters), but simultaneously these systems 
generally have the least amount of toxicity.  Likewise, the more stable functionalities 
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used in the poly(amide) and carbohydrate vectors deliver at concentrations lower than 
their less stable counterparts, but also typically have higher toxicity.  Ultimately, the 
decrease in toxicity enables high dose concentrations which are required to compete or 
exceed the transfection efficiency of their nondegradable counterparts.  For example, the 
poly(β-aminoester) shown in Figure 3.1 had efficiency (Polymer:DNA ratio = 60:1) 
greater than the field standard poly(ethylenemine) (Polymer:DNA ratio = 1:1) and rivaled 
that of adenovirus efficiency, but also required 60 times more material. 26 
 
 
Figure 3.1. Polymer structures; a) poly(β-aminoester), b) poly(ethyleneimine) (PEI), c) 
poly(diethylaminoisoprene) (PEAI) 
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Scheme 3.1. top: Diels Alder synthesis of the diacid monomer (D1) and new target monomer 
(D2); bottom: amine containing degradable copolymer synthesis 
 
 
Our group has developed a novel delivery vector (Figure 3.1), 
poly(diethylaminoisoprene) (PEAI), that showed competitive results to PEI with an N/P 
ratio of 4, and greater efficiency at a ratio of 2.27,28  Despite these promising results, the 
materials showed some degree of toxicity, and in an attempt to minimize this property, it 
was desired to install the allylic dialkylamino functional group of PEAI into a degradable 
system.  Our group has developed a strategy to incorporate diene monomers into a 
biodegradable scaffold via a Diels Alder cycloaddition with fumaric acid followed by a 
polycondensation polymerization (Scheme 3.1).29  As a proof of concept the monomer 
diethylaminoisoprene, which was used in the delivery material PEAI, was reacted with 
fumaric acid to achieve an amine containing diacid (D1).  This was then copolymerized 
with an unfunctionalized dimethylcyclohexene diacid and octanediol, and a series of 
materials with varied diacid feed ratios was synthesized.  It was found that the amino 
diacid could only be incorporated up to 50% relative to the unfunctionalized monomer.  
Above 50% incorporation, the polymer was insoluble and only swelled in solvent; likely 
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due to a crosslinking reaction through the unsaturated portion of the ring.  At 50% amine 
incorporation, the functionality was too dilute for a delivery vehicle.  As a response, in 
the current research a methylated analogue of D1 was designed to create a 
tetrasubstituted double bond in order reduce its reactivity and prevent crosslinking 
(Scheme 3.1).  By avoiding network formation, homopolymers of an amine containing 
diacid could be synthesized and then evaluated for its toxicity, DNA binding, and 
transfection ability.  The goal of this work was the creation of a material that incorporated 
functionality with proven high transfection ability that also minimized unwanted 
cytotoxicity. 
 
2. Experimental Details 
2.1 Materials.  Plasmid DNA (pCMV-Luc) was purchased from Elim 
Biopharmaceuticals, Inc. (Hayward, CA).  Minimum essential medium (MEM), Hanks’ 
balanced salt solution (HBSS), Dulbecco’s phosphate buffered saline (PBS), fetal bovine 
serum (FBS), and a 1 kb DNA ladder were purchased from Invitrogen.  CellTiter 96 
AQueous one solution cell proliferation assay and luciferase assay system were 
purchased from Promega Corp. (Madison, WI).  BCA protein assay kit was purchased 
from Pierce (Rockford, IL).  Branched poly(ethyleneimine) with a molecular weight of 
25,000 g/mol was used as a control in the characterization experiments.  All other 
chemicals were purchased from Sigma-Aldrich and were used without further 
purification.   
2.2 Instrumentation.  1H and 13C NMR spectra were acquired in deuterated 
chloroform or deuterated water on a Bruker 400 AVANCE spectrometer.  Molecular 
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weights were measured by a Waters GPC system using polystyrene standards.  The 
measurements were taken using THF as the solvent on four columns (Waters Styragel 
HR0.5, HR2, HR4, and HR5).  Glass transition temperatures were measured with a Seiko 
220C differential scanning calorimeter, using a heating and cooling rate of 10 °C/min.  
The glass transition temperatures were reported based on the second heating.  
Thermogravimetric analysis was carried out using a Perkin Elmer TGA 7 with a heating 
rate of 10 ºC/min in a N2 atmosphere.  The size and polydispersity of polyplexes was 
analyzed via dynamic light scattering (DLS) using a 90Plus Particle Size Analyzer 
(Brookhaven Instruments Corporation).  Cell culture plates were analyzed on a Molecular 
Devices SpectraMax M5.  Ethidium bromide stained agarose gels were visualized on a 
Bio Rad VersaDoc imaging system. 
2.3 Monomer Synthesis.  2-bromo-N,N-diethylprop-2-en-1-amine.  To a solution 
of N,N-diethylamine in diethyl ether was added 2,3-dibromopropene dropwise at 0 °C 
while stirring.  The reaction was allowed to warm to room temperature and to react for 18 
h.  NaOH (1 M) was added until the formed salt dissolved, and the solution was extracted 
with diethyl ether (50 mL, 3x).  The organic layers were combined, washed with brine, 
dried with MgSO4, and concentrated.  The product was purified and isolated by 
distillation as a colorless liquid.  1H NMR (400 MHz, CDCl3): δ 5.90 (s, 1H), 5.55 (s, 
1H), 3.24 (s, 2H), 2.58 (q, 4H, J = 7.2 Hz), 1.03 (t, 6H, J = 7.2 Hz). 13C NMR (400 MHz, 
CDCl3): δ 132.64 (CH2=CBrCH2), 116.80 (CH2=CBrCH2), 61.46 (CH2N), 46.67 
[N(CH2CH3)2], 11.73 [N(CH2CH3)2] 
2-(N,N-diethylaminomethyl)-3-methyl-1,3-butadiene.  Prop-1-ene 2-magnesium 
bromide (1 M in THF, 0.24 mol) was added dropwise to 2-bromo-3-
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(N,Ndiethylamino)propene (0.20 mol) in the presence of [1,3-
bis(diphenylphosphino)propane]dichloronickel (7.40 x 10-4 mol) at 0 °C. The reaction 
mixture was allowed to slowly warm to room temperature and stirred for 16 h. The 
reaction mixture was then quenched with 300 mL of saturated ammonium chloride 
solution, extracted with diethyl ether (50 mL, 30x), washed once with brine, and dried 
over anhydrous magnesium sulfate. After evaporation of the solvent, the residue was 
distilled to give 2-(N,N-diethylaminomethyl)-1,3-butadiene in 67- 70% yield.  1H NMR 
(400 MHz, CDCl3): δ 5.21 (s, 1H), 5.16 (s, 2H), 4.95 (s, 1H), 3.15 (s, 3H), 2.47 (q, 4H, J 
= 8.0 Hz), 1.89 (s, 3H), 0.98 (t, 6H, J = 8.0 Hz) 
Synthesis of 4-((diethylamino)methyl)-5-methylcyclohex-4-ene-1,2-dicarboxylic 
acid.  2-(N,N-diethylaminomethyl)-3-methyl-1,3-butadiene (2.0 g, 13.04 mmol) was 
added to a flask containing a solution of fumaric acid in ethanol (1.82 g, 15.65 mmol in 
20 mL ethanol).  The mixture was brought to reflux and stirred for 5 days.  The solid 
product precipitated out of solution and was filtered and rinsed with ethanol to yield the 
pure product in 51.2 % yield.  1H NMR (300 MHz, D2O) δ ppm 6.04 (s, 1H), 3.78 (dd, 
2H), 3.18 (tt, J = 13.34, 13.34, 6.55, 6.55 Hz, 4H), 2.76-2.72 (m, 2H), 2.40-2.19 (m, 4H), 
1.75 (s, 3H), 1.27 (t, J = 7.30, 7.30 Hz, 6H).  13C NMR (100.61 MHz, D2O) δ (ppm) 
181.31 and 181.28 (-CO2H), 138.47 (=C-CH2N-), 118.15 (=C-CH3), 109.99 
(CH2=CHCCH2N), 54.57 (-CH2-N-), 47.33 and 46.99 (-N(CH2CH3)2, 34.22(-CH-CO2H), 
30.96 (-CH2-CH=), 19.01 (-CH3), 8.51 and 8.49 (-N(CH2CH3)2 
4,5-dimethylcyclohex-4-ene-1,2-dicarboxylic acid.  2,3-dimethylbuta-1,3-diene 
(10.0 g, 0.121 mol) was added to a flask containing a solution of fumaric acid (14.13 g, 
0.121 mol) in 50 mL ethanol.  The mixture was brought to reflux and stirred for 5 days.  
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The solvent was removed and the product was partitioned between water and diethyl 
ether (50 mL, 30x).  The organic layers were combined, washed once with brine, and 
dried over anhydrous magnesium sulfate.  Pure product was isolated after 
recrystallization from water and ethanol.  1H NMR (400 MHz, D2O) δ (ppm) 2.69 
(m,2H), 2.07-2.26 (m, 4H), 1.55 (s, 6H). 13C NMR (100.61 MHz, D2O) δ (ppm) 177.56 (-
CO2H), 125.62 (=C(CH3)CH2-), 43.45 (-CH-CO2H), 35.75 (-CH2-C(CH3)=), 19.72 (-
CH3) 
2.4 Polyester Synthesis.  A 10 mL round bottom flask was charged with the 
dicarboxylic acids (1.0 eq total) and 1,8-octanediol (OD, 1 eq) or tetraethyleneglycol 
(TEG, 1 eq).  For each material approximately 1 g of diol was used.  The flask was 
sealed, evacuated, and refilled with nitrogen gas.  A homogenous melt was formed by 
heating the flask to 165 ºC while stirring.  Tin octanoate (0.01 equiv) was added to the 
melt.  The reaction mixture was allowed to stir for 1 h.  The temperature was increased to 
170 oC and the pressure was reduced to 20 torr for 17 h, followed by 2 torr for 6 h (OD 
containing materials) or 30 h (TEG containing materials).  At this time, the reaction 
mixture was allowed to cool and dissolved in chloroform.  This solution was precipitated 
into stirring methanol (OD containing) or hexanes (TEG containing) at -78 ºC.  Solvent 
was decanted from the polymer, and the solid was dried in a vacuum oven at 50 °C for 24 
h.  
Poly(octanediol 4,5-dimethylcyclohex-4-ene-trans-1,2-dicarboxylate-co-
octanediol 4-(N,N-diethylaminomethyl)-5-methyl-cyclohex-4-ene-trans-1,2-
dicarboxylate).  1H NMR data in the series of copolymers varies only by the integration 
area for peaks corresponding to protons in the diacid portion of the molecule.  1H NMR 
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(400 MHz, CDCl3) δ ppm 5.27 (s, 1H), 4.07-3.97 (m, 8H), 2.87 (s, 2H), 3.02-2.93 (m, 
2H), 2.87-2.73 (m, 3H), 2.50-2.57 (m, 1H), 2.5-2.37 (m, 6H), 2.31-2.25 (m, 1H), 2.25-
2.19 (m, 1H) 2.19-2.09 (m, 2H), 1.68 (s, 3H), 1.61 (s, 6H), 1.59-1.54 (m, 4H), 1.37-1.26 
(m, 8H), 0.99 (t, 6.58Hz, 6H).  13C NMR (100.61 MHz, CDCl3) δ ppm 174.98 (-CO2-), 
174.84 (-CO2-, amine), 174.70 (-CO2-), 126.57 (=C-CH2-N), 123.88 (=C-CH3), 109.49 
(=C-H), 64.43 (-CO2-CH2-), 54.21 (=C-CH2-N), 46.26 (N-CH2CH3), 41.79 (-CHCO2-), 
40.12 (-CHCO2-), 34.43 (-CH2-CHCO2-), 31.05 (-CH2-CHCO2-), 29.97 (-OCH2CH2CH2-
CH2-), 28.37 (-OCH2-CH2-), 25.61 (-OCH2CH2-CH2-), 18.45 (-CH3), 11.50 (NCH2CH3) 
Poly(tetraethyleneglycol 4,5-dimethylcyclohex-4-ene-trans-1,2-dicarboxylate-co-
tetraethyleneglycol 4-(N,N-diethylaminomethyl)-5-methyl-cyclohex-4-ene-trans-1,2-
dicarboxylate). ).  1H NMR data in the series of copolymers varies only by the integration 
area for peaks corresponding to protons in the diacid portion of the molecule.  1H NMR 
(400 MHz, CDCl3) δ ppm 4.09 (br, 8H), 3.55 (s, 3H), 3.52 (br, 12H), 2.91 (br, 2H), 2.72 
(br, 4H), 2.37 (br, 4H), 2.24-2.03 (m, 2H), 1.57 (s, 3H), 1.49 (s, 6H), 1.10 (m, 8H), 0.89 
(br, 6H).  13C NMR (100.61 MHz, CDCl3) δ ppm 178.88 (-CO2-) 123.71 (=C-), 70.42 (-
OCH2CH2OCH2CH2O-), 68.92 (-OCH2CH2OCH2CH2O), 61.39 (-
OCH2CH2OCH2CH2O), 54.06 (-OCH2CH2OCH2CH2O), 47.76 (N-CH2CH3), 41.76 (-
CHCO2-), 40.18 (-CHCO2-), 33.89 (-CH2-CHCO2-), 30.88 (-CH2-CHCO2-), 18.55 (-
CH3), 11.11 (NCH2CH3) 
2.5 Polymer/Polyplex Characterization.  Standard Polyplex Formation.  To 1 
mg of each polymer sample was added 15 µL of glacial acetic acid followed by 485 µL 
of either opti-MEM or MEM media to make polymer solutions at a concentration of 2 
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mg/mL.  Once dissolved the polymer samples were diluted with the appropriate media to 
obtain the polymer solutions at concentrations of 0.1 mg/mL.  To solutions of 2 µg/mL 
pCMV-Luc plasmid in media was added the polymer solution and media to form 
complexes at desired N/P ratios with total volumes of 200 µL. 
Agarose Gel Electrophoresis.  DNA quenching was monitored over a range of 
DNA to polymer ratios (w/w).  The polymer solutions were made as described above.  
Then desired amounts were titrated into a solution containing 10 µg of plasmid DNA.  
Electrophoresis was conducted on a 0.75% agarose gel in TAE buffer containing 0.5% 
ethidium bromide for 45 min. at 120 V.  The bands were visualized using ethidium 
bromide staining.  
Cytotoxicity Assay.   HeLa cells were grown in 96-well plates at a density of 
5×103 cells/well in 150 µL of growth medium (89% MEM, 10% FBS, 1% L-glutamine).  
Cells were grown for 24 h.  The media was removed, and the cells were washed with 100 
µL of DPBS and incubated with solutions containing MEM and polymer for 4 h.  The 
solutions were removed, and the cells were washed with DPBS.  Following the addition 
of 150 µL of MEM, the cells were allowed to recover for 4 h.  The solutions were 
removed, and the cells were washed with DPBS.  To the cells were added 100 µL of 
MEM and 20 µL of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazoleum, inner salt (MTS, from CellTiter 96 AQueous One Solution 
Cell Proliferation Assay kit).  The cells were incubated for 4 h and the absorbance at 490 
nm was monitored on a Molecular Devices SpectraMax M5 plate reader.    
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Transfection Efficiency Assay.  HeLa cells were grown in 48-well plates at a 
density of 1.5×104 cells/well in 300 µL of growth medium (89% MEM, 10% FBS, 1% L-
glutamine).  Cells were grown for 24 h.  The media was removed, and the cells were 
washed with 300 µL of HBSS and incubated with 450 µL of opti-MEM and 50 µL of 
polyplex solution for 4 h.  The solutions were removed, and the cells were washed with 
HBSS and incubated with 500 µL of opti-MEM (89% MEM, 10% FBS, 1% L-glutamine) 
for 32 h.  The growth medium was removed and the cells were washed with 300 µL of 
HBSS and treated with 150 µL of cell lysis buffer (1X).  The resulting mixtures were 
centrifuged and 20 µL of supernatant were added directly to white opaque 96-well plates.  
Luciferase activity was quantified by adding 100 µL of luciferase assay reagent, followed 
by a 2 second delay.  Luminescence was quantified over a 10 second read time.  The 
result was normalized to the total protein content using a BCA protein assay whose 
absorption was monitored at 562 nm on a Molecular Devices SpectraMax M5 plate 
reader. 
DLS and Zeta Potential Measurements.  Plasmid solutions were made by diluting 
130 µL of pCMV-Luc (1 mg/mL) with 1.37 mL of 0.9% saline to give a final DNA 
concentration of 100 µg/mL.  Polymer solutions were made by dissolving 1 mg of 
material with 15 µL of glacial acetic acid and then diluted with 0.9% saline to reach a 
final concentration of 0.1 µg/mL.  The final pH of the polymer was verified to be 7.4.  
Polyplexes were formed at N/P ratios of 1, 2, 4, 10, and 20, allowed for a 20 minute 
equilibration time, and the complex diameters and ζ-potentials were monitored. 
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3. Results and Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3.2. a) Synthesis of 2-(N,N-diethylaminomethyl)-3-methyl-1,3-butadiene and of 4-
((diethylamino)methyl)-5-methylcyclohex-4-ene-1,2-dicarboxylic acid (D2); b) amine containing 
degradable copolymer synthesis containing octanediol; c) amine containing degradable 
copolymer synthesis containing tetraethyleneglycol; (X = percent D2 feed) 
 
 
3.1 Synthesis.  The aminodiene 2-(N,N-diethylaminomethyl)-3-methyl-1,3-
butadiene was synthesized as seen in Scheme 3.2.  This diene as well as 2,3-
dimethylbutadiene were then reacted with fumaric acid via a Diels Alder cycloaddition to 
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afford the target monomers 4-((diethylamino)methyl)-5-methylcyclohex-4-ene-1,2-
dicarboxylic acid (D2) and 4-((dimethylamino)methyl)cyclohex-4-ene-1,2-dicarboxylic 
acid (D3) in high purity.  The diacid monomers were then copolymerized in bulk with 
octanediol (OD) or tetraethyleneglycol (TEG), using a tin octanoate catalyst at elevated 
temperatures and reduced pressure (Scheme 3.2).  The monomer ratios were varied from 
20% up to formation of the amine functionalized homopolymer with octanediol (Table 
3.1).   To increase solubility a shorter series of materials were made, replacing the 
octanediol with the more hydrophilic TEG and materials with 0, 60, and 100% amino 
diacid feed were synthesized.   
In both series of materials there was good fidelity between the feed and 
incorporation, with the amine monomer always slightly lower than expected (Table 3.1).  
As the incorporation of the D2 increased, the molecular weights decreased.  The PDI of 
the OD containing systems were between 1.3-1.8, showing some molecular weight 
fractionation during work up.  The PDI of the TEG containing materials however 
increased with amine incorporation with no apparent fractionation.  Purification of the 
latter materials was carried out in hexanes at -78 oC due to the increased hydrophilicity as 
opposed to methanol used in the OD systems.  To reach comparable molecular weights of 
the OD materials, the reaction time for the TEG materials was increased from 24 to 48 
hours with the time at full vacuum being increased from 6 to 30 hours.  The difference in 
polymerization may stem from the ether diol interacting with the coordination sites of the 
tin catalyst decreasing its effectiveness in catalyzing ester formation. 
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There was one glass transition between -5 and -13 oC for the OD materials and -
13 to -18 oC for the TEG materials.  The combination of high fidelity between the feed, 
as well as the single Tg transition, supports the formation of random copolymers.  Due to 
the poor solubility of the OD containing material, all further characterization (toxicity, 
complex size and charge, DNA binding, and transfection) was done only on the TEG 
materials.  
 
Table 3.1 Homo- and copolymerization of D2 and D3, with either OD or TEG 
Sample Feed
a
 
(%) 
Incorp.b 
(%) 
Yield 
(%) 
‹Mn›c 10-3 
(g/mol) PDI
c
 Tgd 5%e 10%e 
PI-0 0 0 81 16.3 1.7 -13 359 372 
PI-20 20 16 72 14.1 1.8 -10 337 357 
PI-40 40 33 76 9.4 1.6 -14 325 353 
PI-60 60 51 39 6.3 1.7 -7 281 326 
PI-80 80 65 39 5.7 1.3 -5 278 320 
PI-100 100 100 33 6.1 1.5 -8 288 326 
PII-0 0 0 75 12.0 1.9 -13 278 321 
PII-60 60 58 95 3.5 2.0 -15 263 314 
PII-100 100 100 87 4.0 3.0 -18 235 293 
a  amine monomer  relative to the DPAI; b determined by 1H NMR; c determined by GPC; d 
determined by DSC; e percent decomposition determined by TGA 
 Figure 3.2. Cytotoxicity of PII
 
 
3.2 Polyplex/Biological 
evaluated to determine if utilizing a degradable scaffold yielded materials with a low 
toxicity profile.  To do this, 
100, and PEI at concentrations r
toxic compared to the nondegradable material, with PII
toxicity at concentrations greater than 50 
than PII-60, which has less cationic sites.  This was not expected since toxicity of gene 
delivery materials is usually associated with the charge density, and future studies will 
focus on evaluating the toxicity of the nonfunctionalized monomer (D3).
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Characterization.  The in vitro cytotoxicity was 
an MTS assay (Figure 3.2) was performed with PII
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Table 3.2. Complex size and surface charge measurements 
 
PEI PII-60 PII-100 
N/P Size
a
 
(nm) ζ-potential
a
 
Sizea 
(nm) ζ-potential
a
 
Sizea 
(nm) ζ-potential
a
 
1 146 -25.6 309 -30.5 402 -31.7 
2 314 -19.6 220 7.6 325 1.9 
4 347 20.9 272 31.8 332 29.1 
10 346 22.6 222 45.0 363 33.9 
20 358 27.2 322 42.6 464 35.1 
a
 determined by a 90Plus Particle Size Analyzer 
 
 
The properties of the polyplexes were then evaluated for surface charge (ζ-
potential) and complex size (Table 3.2).  For nontargeted transfection, it is important for 
the complex to maintain a positive surface charge to interact with the cell surface.  
Complexes were formed between the TEG materials (PII) or PEI and a 6000 base pair 
plasmid, pCMV-Luc.  The ζ-potentials revealed that both of the polyesters reached a near 
neutral charge around an N/P ratio of 2, and PEI was between 2 and 4.  Requiring a lower 
concentration to create a positive surface for the PII materials was promising since they 
could potentially transfect at lower concentrations than PEI.  Complex sizes were then 
measured by dynamic light scattering.  The average diameter of the unbound plasmid was 
~750 nm, and it was shown that each material was able to complex DNA and form a 
more compact structure. 
 
  
Figure 3.3. Transfection experiments of PII
of 20 for the polyesters and N/P of 4 for PEI
 
 
 Based on the results of low toxicity, ability to compact DNA, and positive 
surface charge at low concentrations, the materials were evaluat
ability.  For the transfection experiments, the same pCMV
luciferase reporter gene was used
Figure 3.3, at an N/P of 20 the polyesters showed poor tra
performing 1000 fold lower than PEI (whose optimum performance was taken at an N/P 
of 4).  Despite concentrations well above charge neutrality and complexation, there was 
no bioactivity.  The DLS experiments
formation without distinguishing
characterize the complex formation, DNA binding gels were used.
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Figure 3.4. Agarose gel electrophoresis assay; lane L) DNA molecular ladder; lane P: Naked 
DNA; lane A) 5:10 (polymer/DNA w/w ratios); lane B) 10:10; lane C) 20:10; lane D) 40:10; lane 
E) 50:10 
 
 
The DNA binding ability was investigated using agarose gel electrophoresis to 
determine the polymer concentrations that PII-100 could effectively bind DNA (Figure 
3.4).   In this test when a current was applied, naked DNA migrated down the gel.  As 
aliquots of cationic material were added, the electrostatic interactions resulted in charge 
neutralization and migration of the DNA bind was quenched.  Polymer/DNA complexes 
were formed at ratios from 0 µg to 50 µg of polymer with 10 µg of DNA.  As seen in 
Figure 3.4, even at high polymer concentrations, there was no effective DNA binding, or 
complex formation. With a molecular weight of the repeat unit near 500 g/mol, a material 
with only a total molecular weight of 4000 g/mol would only have eight amines per 
polymer chain.  Transfection efficiency is greatly dependent on the amine density in 
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order to complex DNA and to serve as a ‘proton sponge’ for endosomal release, and the 
poor results of these materials may stem from their low amine density.   
 
4. Conclusions 
A facile Diels Alder reaction between a functionalized diene and fumaric acid was 
exploited to synthesis an amine functionalized monomer.  Previously, materials utilizing 
this chemistry were limited to an upper limit of 50% incorporation of the amine monomer 
with higher feed ratios resulting in crosslinking.  A new monomer was developed that 
utilized a tetrasubstituted double bond to prevent crosslinking.  After successful synthesis 
of this monomer, a series of degradable tertiary amine containing copolymers and a 
homopolymer were synthesized.  Installment of the methyl group on the double bond was 
successful in limiting crosslinking and permitted development of the amine 
homopolymer.  Two types of polyesters were synthesized, the first containing octanediol, 
and the second containing tetraethyleneglycol.  The former was found to have poor 
solubility, and the latter materials were used in the biological characterization 
experiments.  It was shown that the degradable system was much less toxic than the 
control (PEI), but only formed weak complexes with DNA and ultimately had low 
transfection efficiency.  Only low molecular weight material was synthesized, resulting in 
low amine density.  This most likely led to the materials poor delivery performance. 
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Chapter 4.  Developing Guanidine Functionalized Materials for 
Enhanced Cellular Uptake 
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Abstract.  To date, the most common functionalities used in synthetic gene therapy 
materials are 1o, 2o, and 3o amines. These groups, however, are generic, serving as 
cationic sites for DNA complexation and cell membrane association, as well as providing 
a buffering potential for endosomal release.  In this research, a specialized functionality, 
guanidine, was identified to enhance cell association and uptake.  Herein, multiple 
strategies have been developed for synthesizing a guanidine functionalized diene.  The 
most promising of which utilizes a tosylated hydroxyisoprene intermediate that can be 
rapidly synthesized and is stable at 4 oC.  This intermediate has also been used to produce 
tertiary amine functionalized dienes and could potentially serve a general method for the 
preparation of 2-functionalized isoprene. 
 
1. Introduction 
Viral based gene delivery vehicles offer the most efficient method for cell 
transfection.1,2  Viral machinery has evolved to impart target specificity, cellular uptake, 
endosomal release, and nuclear localization that results in enhanced bioactivity.3  
Unfortunately, there are inherent problems with the use of viruses.  After repeated 
administration, the body may gain natural immunity and diminish the effectiveness of 
delivery.  Furthermore, natural vectors have been shown to elicit immune or 
inflammatory responses.  Depending on the viral type, some vectors have the ability to 
insert their DNA directly into the host’s chromosome which may disrupt expression of 
integral proteins.  These issues have limited viral delivery, resulting in cancer and death 
in phase III clinical trials.4,5 
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 As a response, synthetic materials are being designed that are not recognized by 
the immune system and have shown limited inflammatory response.6-18  To compete with 
the natural systems, synthetic polymers must efficiently 1) form a complex with DNA 
(polyplex), 2) associate to the cell membrane and become internalized through 
endocytosis, 3) escape from the endosome, 4) transport the cargo to the nucleus, and 5) 
dissociate from the DNA.19  To date few materials have been developed with efficiency 
that competes with viral delivery.  One strategy to increase efficiency is incorporating 
cationic functionalities beyond the typical 1o, 2o, and 3o amines with the potential to 
decrease toxicity, increase buffering capacity (endosomal release), and enhance cellular 
uptake.  Two functionalities that have been commonly utilized are pyridine and imidazole 
groups.13,20-22  It has been shown that cationic groups with the charge in resonance 
typically had decreased toxicity.23  Due to the lower pKa values, pyridine and imidazole 
also increased the buffering capacity of the polymer by remaining unprotonated until 
acidification inside the endosome.  While these groups focus on the issues of toxicity and 
buffering, they do not address increasing cellular uptake efficiency; one of the key 
aspects of viral vectors. 
One way viruses achieve their efficiency is by utilizing membrane permeable 
proteins that associate to the cell membrane and activate cellular uptake.  In a series of 
these proteins, the amino acids that that have been identified as critical for uptake have a 
high occurrence of cationic amino acids, most notably arginine (Table 4.1).18  The 
functional group of arginine is a guanidine moiety which has been shown to form 
electrostatic interactions and two hydrogen bonds between anionic groups such as 
phosphates and sulfates on the cell surface. Binding of these groups can signal for 
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uptake.24,25  This binding also results in a neutral charge, promoting condensation on the 
cell surface, also increasing the rate of cellular uptake.   
 
Table 4.1. Membrane permeable peptides, the active sequences, and relative translocation 
efficiency (amino acid position)26 
 
Peptides Sequences Translocation Efficiency 
Tat and the related peptides 
  
HIV-1 Tat(48–60) GRKKRRQRRRPPQ + + + 
R9-Tat GRRRRRRRRRPPQ + + + 
Other RNA binding peptides 
 
 
HIV-1 Rev(34–50) TRQARRNRRRRWRERQR + + + 
FHV Coat(35–49) RRRRNRTRRNRRRVR + + + 
CCMV Gag(7–25) KLTRAQRRAAARKNKRNTR + + 
P22 N(14–30) NAKTRRHERRRKLAIER + + 
l N(1–22) MDAQTRRRERRAEKQAQWKAAN + 
j 21 N(12–29) TAKTRYKARRAELIAERR + 
Yeast PRP6 (129–144) TRRNKRNRIQEQLNRK + 
Human U2AF(142–153) SQMTRQARRLYV - 
 
 
Materials have been previously developed incorporating guanidine groups with 
success in increasing cellular uptake and transfection.27-31  The most basic of these were 
oligo-arginine peptides, with which efficient transfection was successful with optimal 
chain lengths between 7 and 9 amino acids.30  Another material was developed by 
Ferrutti, where a poly(amidoamine) was synthesized with a carboxylic acid and guanidine 
moiety in every repeat unit.27,28  This material was shown to have low toxicity and 
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efficiencies comparable to jetPEI, a commercially available linear poly(ethyleneimine) 
delivery system.  The functional group has also been placed at the periphery of poly(L-
lysine) dendrimers.32  When compared to the nonfunctionalized dendrimer, the membrane 
transport was greatly enhanced.  Guanidine has repeatedly proven to be an integral 
functional group in natural and synthetic delivery vehicles.   
Previously, we reported a series of dialkylamino functionalized dienes  with one, 
poly(diethylaminoisoprene) (PEAI), that was shown to have higher transfection 
efficiency than PEI at low concentrations.15  This material showed efficiency better than 
PEI at an N/P ratio of 2 (N/P ratio = the number of amines of the polymer divided by the 
number of phosphates of the DNA).  Incorporating a guanidine moiety may increase 
cellular uptake and enhance its bioactivity.  A 2-substituted diene would be an analogous 
monomer to that used in our initial studies with PEAI, but difficulty arises in 
functionalizing a diene in this position.  Current methods are tedious and no general 
procedure exists.33  Incorporation of the functionality can be achieved through 
substitution by a guanidine moiety (guanidinylation)34-36 or by conversion of a 1o or 2o 
amine to a guanidine moiety (guanylation).32,37,38  Current research focuses on developing 
strategies to create a guanidine functionalized isoprene.  Once obtained, a series of 
copolymers with diethylaminoisoprene (DEAI) will be synthesized and an optimized 
monomer feed for transfection will be established.  Through this work, an enhanced 
delivery vehicle may be produced and the value of functionalizing existing and future 
materials with the guanidine group may be further supported.  Furthermore, this work 
will also develop a facile path to synthesizing dienes functionalized in the 2-position. 
 
89 
 
2. Experimental 
2.1 Materials and Instrumentation.  Chloroprene was purchased from Pfaltz 
and Bauer Inc, and used after distillation.  All of the other reagents were purchased from 
Aldrich.  Isoprene was freshly distilled before each reaction.  All other chemicals were 
used without further purification.  1H and 13C NMR spectra were acquired in deuterated 
chloroform or dimethylsulfoxide on a Bruker 400 AVANCE spectrometer or Bruker 300 
AMX spectrometer.  Molecular weights were measured by a Waters GPC system using 
polystyrene standards.  The measurements were taken using THF as the solvent on four 
columns (Waters Styragel HR0.5, HR2, HR4, and HR5). 
2.2 Bromoisoprene.  3-Methyl-2,5-dihydrothiophene-1,1-dioxide.39  Liquid 
Sulfur dioxide (~ 50 mL) was collected using an acetone/dry ice cold finger.  A 300 mL 
Parr reactor, cooled to -10 oC, was then charged with isoprene (68 g,) methanol (40 mL), 
SO2(l), and hydroquinone (2.5 g).  The vessel was sealed and then heated to 85 oC while 
stirring for 4h.  The system was allowed to return to room temperature, and the product 
was poured into 300 mL of dIH2O and cooled to 4 oC overnight.  The mixture was 
filtered to yield 64.6 g (64% yield) of off-white crystals.  1H NMR (300 MHz, CDCl3): δ 
5.68 (s, 1H), 3.79 (s, 2H), 3.68 (s, 2H), 1.89 (s, 4H) 
3-Bromomethyl-2,5-dihydrothiophene-1,1-dioxide.40  To a 1 L round bottom flask 
equipped with a condenser was added 3-methyl-2,5-dihydrothiophene-1,1-dioxide, 
benzoyl peroxide, N-bromosuccinamide (57 g, 0.32 mol, NBS) and chloroform (500 mL).  
The mixture was stirred at reflux for 24 h.  The solvent was then concentrated by rotary 
evaporation, cooled to 4 oC for 12 h, followed by vacuum filtration to remove the 
succinimde byproduct.  The remaining solvent was removed via rotary evaporation, and 
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the resulting solid was purified by recrystallization from 95% ethanol yielding 8.21 g 
(12.2% yield) of product as an off-white powder. 1H NMR (300 MHz, CDCl3): δ 6.10 (s, 
1H), 4.03 (s, 2H), 3.88 (s, 4H) 
2-Bromomethyl-1,3-butadiene (1)40.  To a 100 mL round bottom flask equipped 
with a distillation apparatus was added 3-bromomethyl-2,5-dihydrothiophene-1,1-dioxide 
(8.21 g, 0.039 mol) and hydroquinone (~ 10 mg).  The flask was heated to 170 oC with 
continuous distillation at 200 torr.  The product (1.4 g, 24%) was obtained as a greenish 
brown liquid. 1H NMR (400 MHz, CDCl3): δ 6.30–6.34 (dd, 1H), 5.46 and 5.40 (d, 1H), 
5.40 (s, 1H), 5.28 and 5.25 (d, 1H), 5.25 (s, 1H), 4.11 (s, 2H) 
1,3-(di-tert-butoxycarbonyl)guanidinoisoprene (2).  To a 50 mL round bottom 
equipped with a drying tube was added sodium hydride (0.51, 0.21 mol) followed by dry 
DMF (6 mL) over ice.  A solution of 1,3-(di-tert-butoxycarbonyl)guanidine (2.88 g, 
0.011 mol) dissolved/suspended in dry THF (10 mL) was added dropwise and allowed to 
stir for 30 min.  1 was then slowly added and the reaction was stirred at room temperature 
for 18 h.  To quench the remaining NaH, dIH2O was added and the product was extracted 
with diethyl ether (50 mL, 3x).  The organic layer was then washed with dIH2O (50 mL, 
3x) to remove the remaining DMF.  The organic layers were then combined, washed with 
brine, dried with MgSO4, and concentrated.  The product was then purified by column 
chromatography with 5% EtOAc/Hexane as the eluent to yield 2 (2.62 g, 72 % yield). 1H 
NMR (400 MHz, CDCl3): δ 6.37–6.45 (dd, 1H), 5.28 and 5.22 (d, 1H), 5.11 and 5.08 (d, 
1H), 5.06 (s, 1H), 4.83 (s, 1H), 4.78 (s, 2H), 1.49 (s, 9H), 1.44 (s, 9H). 13C NMR (100.61 
MHz, CDCl3): δ 163.66 (C=O), 160.65 (C=O), 154.82 (C=N), 142.41 (CH2=CCH2N), 
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137.00 (CH2=CHCCH2N), 113.54 (CH2=CHCCH2N), 112.66 (CH2=CCH2N), 83.59 
(CH2N), 78.53 (C[(CH3)3]2), 28.17 and 27.65 ([(CH3)3]2) 
poly(1,3-(di-tert-butoxycarbonyl)guanidinoisoprene).  AIBN (5.05 mg, 0.03 
mmol, monomer 2 (1g, 0.003 mol), and dioxane (0.5 mL) were added to an ampoule with 
a magnetic stir bar. After three freeze-pump-thaw cycles, the ampoule was sealed under 
nitrogen and placed in an oil bath preheated to 50 °C.  After 5 d, methylene chloride (2 
mL) was added to the polymer solution and the polymer was precipitated into methanol at 
-78 °C and dried under vacuum at room temperature for 5 d. 1H NMR (400 MHz, 
CDCl3): δ 5.04 (s, 1H), 4.71 and 4.53 (s, 2H from trans and cis CH2N, respectively), 2.05 
and 1.90 (s, 4H from trans and cis respectively), 1.46 (s, 18H) 
2.3 Hydroxyisoprene.  1-((2-bromoallyl)oxy)-4-methylbenzene (4).  To a 100 mL 
round bottom equipped with a drying tube was added sodium hydride (0.51, 0.21 mol) 
followed by dry DMF (20 mL) over ice.  To the solution was added 4-methoxyphenol 
(13.7 g, 0.11 mol) dropwise and allowed to stir for 30 min.  2,3-dibromopropene (25 g, 
0.1 mol) was then slowly added and the reaction was stirred at room temperature for 18 h.  
To quench the remaining NaH, dIH2O was added and the product was extracted with 
diethyl ether (50 mL, 3x).  The organic layer was then washed with dIH2O (100 mL, 3x) 
to remove the remaining DMF.  The organic layers were combined, washed with brine, 
dried with MgSO4, and concentrated.  The purified product 1-((2-bromoallyl)oxy)-4-
methylbenzene (4) was purified by distillation at 130 oC and 2 torr to yield 18.3 g of 4 
(63 % yield). 1H NMR (400 MHz, CDCl3): δ 6.83-6.90 (m, 4H), 6.0 (s, 1H), 5.67 (s, 1H), 
4.60 (s, 2H), 3.78 (s, 3H) 
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((2-bromoallyl)oxy)trimethylsilane (6).  To a 25 mL round bottom flask 
containing 2-bromoalcohol (5 g, 0.036 mol) in DMF (7 mL) was added imidazole (6.2 g, 
0.091 mol).  Chlorotrimethylsilane (5.8 mL, 0.0457) was then added dropwise at 0 oC and 
allowed to stir for 18 h.  The reaction mixture was added to diethyl ether (25 mL) and 
extracted with dIH2O.  The water layer was extracted with diethyl ether (50 mL, 3x).  The 
organic layers were combined and the back extracted with dIH2O (25 mL, 2x), washed 
with brine, dried with MgSO4, and concentrated via rotary evaporation.  The product was 
then purified by distillation at 85 oC
 
and 30 torr to yield 6 (4.8g, 63 % yield). 1H NMR 
(400 MHz, CDCl3): δ 5.95 (s, 1H), 5.56 (s, 1H), 4.21 (s, 2H), 0.18 (s, 3H) 
2,5-dihydrothiophene-3-carboxylic acid 1,1-dioxide (7).41  A 300 mL Parr reactor 
was charged with 3-sulfolene (12.06 g, 0.102 mol), 1,8-diazabicyclo[5,4,0]undec-7-ene 
(30.6 mL, 0.205 mol) and dimethylsulfoxide (DMSO, 15 mL).  The reactor was sealed 
and pressurized with CO2 (50 psi) and left stirring at room temperature for 3 d.  The 
mixture was diluted with acetone (50 mL) and filtered.  The solid was then dissolved in 
methylene chloride (500 mL) and dry HCl was bubbled through the solution until 
precipitate stopped forming.  The HCl gas was formed in situ by slow addition of H2SO4 
into mixture of NaCl and concentrated HCl.  The gas was dried through H2SO4 prior to 
reaching the reaction flask.  The solid was isolated by filtration, dissolved in acetone (75 
mL), and passed through a short silica column.  The organic fractions were combined and 
the solvent was removed by rotary evaporation to afford 7 as an off-white solid (9.7g, 
0.06 mol, 59.8 % yield). 1H NMR (400 MHz, DMSO-d6): δ 6.96 (s, 1H), 4.13 (s, 2H), 
3.99 (s, 2H). 13C NMR (100.61 MHz, DMSO-d6): δ 164.12 (C=Ο), 134.78 (CH=C), 
130.58 (CH=C), 58.02 (CHC), 55.01 (CHC=C)  
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hydroxyisoprene (5) (sulfone method).  To a 500 mL round bottom containing 7 
(10 g, 0.062 mol) in THF (100 mL) was added 1M diisobutylaluminum hydride in THF 
(215.8 mL, 0.216 mol) dropwise at 0 oC.  The reaction was allowed to return to room 
temperature and stirred for 18 h.  Excess methanol (200 mL) was added to the flask 
followed by dIH2O (0.2158 mol) and the formed solid was filtered off.  The filtrate was 
then concentrated by reduced pressure.  Crude: 1H NMR (400 MHz, DMSO-d6): δ 6.00 
(s, 1H), 4.26 (s, 2H), 3.85 (s, 2H), 3.80 (s, 2H).  Deprotection was then carried out at 150 
oC with continuous distillation at 400 torr and briefly reduced to 100 torr in an attempt to 
collect any substantial amount of product.  Only a small amount of 5 was isolated and 
immediately analyzed by proton NMR. 1H NMR (400 MHz, CDCl3): δ 6.30–6.40 (dd, 
1H), 5.30 (s, 1H), 5.26 (d, 1H), 5.15 (s, 1H), 5.12 (d, 1H), 4.34 (s, 2H) 
hydroxyisoprene (5) (chloroprene method).  To a 25 mL round bottom was added 
dry THF (10 mL) followed by magnesium turnings (0.21 g, 0.0085 mol).  The turnings 
were activated by scratching.  To the solution was added dibromoethane (1 mL) and the 
system was cooled to 0 oC.  ZnCl2 (0.023 g, 0.169 mmol) was added and a small amount 
of freshly distilled chloroprene for activation.  The distilled chloroprene (0.5 g, 0.006 
mol) was then added dropwise to maintain slow reflux of the solvent.  The formaldehyde 
was generated by addition of 2,2,6,6-tetramethylpiperdine (1.92 mL, 0.0113 mol) to a 
solution of dry THF (10 mL) and 2 M n-butyllithium in THF (5.65 mL, 0.0113 mol).42  
The solution was cooled to 0 oC and benzotriazolemethanol (1.68 g, 0.0113 mol) was 
added.  The temperature was then reduced to -78 oC and the chloroprene Grignard was 
added dropwise.  The reaction was kept at this temperature for 3 h and then allowed to 
warm to room temperature for 18 h.  The reaction was quenched with diH2O and 
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extracted with diethyl ether (50 mL, 3x).  The organic layers were combined, washed 
with 4 N NaOH (15 mL), brine (15 mL), and dried over MgSO4.  The product mixture 
was concentrated and hydroxyisoprene 5 along with the allene isomer 9 were isolated by 
distillation.  Further separation could not be achieved. 
hydroxyisoprene (5) (ring opening method).  Lithium diisopropylamide (LDA, 
18.2 g, 0.17 mol) was added to an oven dried 1 L round bottom flask.  To the flask was 
then added freshly distilled diethyl ether (300 mL) that was dried over sodium.  The 
epoxide, 2-methyl-2-vinyloxirane (11 g, 0.131 mol) was added dropwise maintaining a 
gentle reflux upon addition.  The solution was then stirred for 3 h and added to 2 N HCl 
(200 mL).  The organic layer was isolated, washed with 5% sodium bicarbonate, brine, 
and then dried over MgSO4.  
The organic layers were concentrated via rotary evaporation yielding the crude product 5 
(5.24 g, 48% yield).  The product was further purified by distillation at 50 oC and 2 torr, 
but the typical percent yields were below 10%.  For this reason the crude product was 
used without further purification. 1H NMR (400 MHz, CDCl3): δ 6.35–6.42 (dd, 1H), 
5.29 (s, 1H), 5.27 (d, 1H), 5.15 (s, 1H), 5.11 (d, 1H), 4.33 (s, 2H) 
tosylisoprene (3).  To a 100 mL round bottom was added methylene chloride (50 
mL) p-toluenesulfonyl chloride (8.3 g, 0.434 mol), and triethylamine (6.05 mL, 0.0434).  
5 was added dropwise at 0 oC for 4 h.  The reaction was poured into hexanes and the solid 
removed by filtration.  The solution was concentrated under reduced pressure to yield the 
crude product 3 (5.09 g, 68 % yield).  1H NMR (400 MHz, CDCl3): δ 7.80 (s, 2H), 7.34 
(s, 2H), 6.24–6.31 (dd, 1H), 5.25 (s, 1H), 5.21 (s, 1H), 5.15 (d, 1H), 5.10 (s, 1H), 4.68 (s, 
2H), 2.46 (s, 3H).  Subsequent small scale substitution reactions were carried out with 
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1,3-(di-tert-butoxycarbonyl)guanidine or diethylamine and initial proton NMR spectrum 
can be found in the supplemental section.  
 
3. Results and Discussion 
Scheme 4.1. Synthesis of Boc protected guanidinoisoprene via a bromoisoprene intermediate 
 
 
3.1 Bromoisoprene 
A few methods have been used for developing 2-substituted dienes.  The first is 
by synthesis of 2-bromoisoprene (1) followed by nucleophilic substitution.  Synthesis of 
1 entails either dehydrohalogenation of brominated isoprene, or bromination of sulfur 
dioxide protected isoprene with N-bromosuccinimide (NBS).  The dehydrohalogenation 
pathway traditionally has low yields, and to avoid the use of excess Br2 (which is both 
toxic and not atom economical) the second method was used to produce the key 
intermediate 1 (Scheme 4.1).  Synthesis began with the protection of isoprene with sulfur 
dioxide, producing an off-white crystalline solid in moderate yields.  The protected 
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isoprene was then brominated in the allylic position with NBS, and after purification by 
repeated recrystallizations, the product was isolated as an off white powder in low yields.  
The target intermediate was then obtained by thermal deprotection at 170 oC while under 
continuous distillation at 200 torr.  Due to the intermediate’s instability and high 
volatility, the yields for this step were also low (24 %).  Once 1 was obtained, it was 
immediately used without further purification.  Guanidinylation was carried out by 
deprotonation of 1,3-(di-tert-butoxycarbonyl)guanidine (Boc2G) with NaH followed by 
slow addition of 1.  Pure product (2) was isolated after column chromatography as an off 
white crystalline powder in moderate yields.  Boc2G-isoprene was polymerized using a 
radical initiator, AIBN, in dioxane at low temperature.  Higher temperature 
polymerizations resulted in insoluble solid.  The Boc protecting group can be removed by 
thermal cleavage, and it is thought that the t-butyl carbocation intermediediate formed 
during removal may initiate a cationic polymerization through the double bond.  The 
isolated polymer was found to have a molecular weight of 35,000 g/mol and a PDI of 1.7.  
Subsequent deprotections of the polymer resulted in crosslinked material.  Due to an 
overall yield of 1%, few attempts were made to vary the deprotection conditions.  This 
pathway also had numerous steps, was time demanding, and utilized an unstable 
precursor 1.  As a response, a synthon to 1 was targeted which replaced the bromide with 
a tosylate leaving group (3, Scheme 4.1). 
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Scheme 4.2. Preparation of hydroxyisoprene utilizing an aryl ether protecting group 
 
 
3.2 Hydroxyisoprene 
The target tosylisoprene intermediate could be formed from hydroxyisoprene (5).  
Our lab has previously synthesized dienes functionalized at the two position.15,43  The 
synthesis employed substitution of 2,3-dibromopropene with the appropriate nucleophile.  
The diene was then formed by coupling with vinyl magnesium bromide using Kumada-
Corriu conditions.  Using this strategy, the synthesis of 3 began with installing a hydroxyl 
protecting group , p-methoxyphenylether (Scheme 4.2).  This began with deprotonation 
of p-methoxyphenol with NaH followed by slow addition of 2,3-dibromopropene.  The 
product was purified by distillation and isolated in 63% yield.  The subsequent Kumada 
coupling only yielded the initial protecting group with no product seen by proton NMR.  
Allylic aryl ethers have been shown to cleave in the presence of Ni(II)/Ni(0) systems 
which are thought to be present in the coupling reaction.44 
 
 
 
Scheme 4.3. Preparation of hydroxyisoprene utilizing a silyl ether protecting group 
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An alternate protecting group (trimethylsilylether; TMS) was then used to avoid 
deprotection during the coupling step.  The protecting group was installed by reacting 
trimethylsilyl chloride with 2-bromoallyl alcohol, and after distillation afforded the pure 
protected bromopropene (6) in moderate yields (Scheme 4.3).  Once again, upon 
coupling, there was no product detected, and the focus was then placed on 
functionalization of a preexisting diene. 
 
 
Scheme 4.4.  Synthesis of hydroxyisoprene by carboxylation and reduction of protected 
butadiene 
 
 
Three pathways were used toward hydroxylation and subsequent tosylation of a 
preformed diene.  The first targeted reduction of isoprene carboxylic acid (7).  As shown 
in Scheme 4.4, synthesis began with carboxylation of sulfolene with 50 psi of CO2(g) in 
the presence of 8-diazabicyclo[5,4,0]undec-7-ene (DBU).  This step occurred selectively 
to afford the target 7.  The acid was then reduced with diisobutylaluminum hydride 
(Dibal) followed by deprotection at 150 oC while under continuous distillation.  The yield 
of the purified product was low, possibly from heat promoted polymerization of the 
monomer prior to distillation. 
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Scheme 4.5.  Synthesis of hydroxyisoprene through a grignard reaction between chloroprene and 
formaldehyde 
 
 
The second pathway was a one step reaction of a Grignard, 2-(1,3-
butadienyl)magnesium chloride (8) with formaldehyde to afford 5 in one step without 
protection and deprotection steps (Scheme 4.5).  Synthesis began with Grignard 
formation of chloroprene.  Simultaneously formaldehyde was generated in situ by 
addition of benzotriazolylmethanol to a solution of LiTMP at 0 oC.  The temperature was 
reduced to -78 oC, the Grignard added slowly, and the system stirred at this temperature 
for 3 hours.  An inseparable mixture of the target monomer and the allene isomer (9) was 
isolated by distillation.  It was previously reported that a reaction between 2-(1,3-
butadienyl)magnesium chloride with formaldehyde yields a mixture of diene and allene 
isomers.45 
 
Scheme 4.6. Synthesis of tosylisoprene from ring opening of 2-methyl-2-vinyloxirane 
 
100 
 
The third strategy targeted selective ring opening of 2-methyl-2-vinyloxirane, 10, 
with a sterically hindered base (Scheme 4.6).  To this end, 10 was slowly added to a 
diethyl ether solution containing lithium diisopropylamide at room temperature and 
allowed to react for 3 hours.  The product was washed with dilute HCl and concentrated 
to afford the crude product 5 in moderate yields.  Purification was possible by distillation, 
but yields were low despite a low temperature distillation.  For this reason, the crude 
product was typically used without purification.  Tosylation of 5 with p-toluenesulfonyl 
chloride afforded the target monomer 3.  Initial substitution of the tosylate was successful 
with guanidine in a similar procedure to the guanidinylation steps previously discussed.  
Furthermore, substitution with diethylamine was also successful.  To date, only small 
scale reactions have been attempted to gain an understanding of the breadth of 
nucleophiles that can be used in the substitution, and current research is focusing on 
optimization and increasing the reaction scale. 
 
4. Conclusions 
 Guanidine functionalized materials may potentially enhance the transfection 
efficiency of delivery vehicles used currently.  Synthetic strategies have been developed 
to produce a guanidine functionalized isoprene to be a comonomer with DEAI to enhance 
an efficient gene delivery material, PEAI, that was developed in our lab.  In an effort 
towards a faster method of producing isoprene substituted off of the 2-postion, two 
monomer intermediates were identified, the first being bromoisoprene and the second 
tosylisoprene.  Through both pathways guanidine functionalized monomers were 
successfully created.  Previous diene syntheses were between 5 to 7 days, and through 
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this work, a method was developed to obtain a monomer intermediate in 2 days.  
Furthermore, this intermediate could react with a wide range of nucleophiles and could 
lead to rapid development of a library of dienes functionalized at the 2-position.  Future 
work will focus on optimization of this pathway and further elaboration of the diene 
library.   
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Chapter 5. General Conclusions 
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 The work described was focused on the development of polycationic materials for 
gene delivery applications.  The variables or properties of these polymers that participate 
in delivery are quite complex and are often in competition.  To date, there have been 
attempts to create guidelines into designing new materials, but there remain no clear rules 
or targets for polymer development.  Three aspects of delivery were targeted to 
fundamentally study the process including pKa and ionization control for endosomal 
release, degradability for lowered toxicity, and a new functionality for enhanced cellular 
uptake.  Control over ionization by programming materials with unique pKa transitions 
afforded insights into optimizing the complexation/buffering potential for designing new 
materials.  In this study the acid/base inflection points for a range of materials were 
varied from an average pKa of 5.8 up to 7.9 through the synthesis of a series of 
copolymers.  It was determined that the materials near an inflection of 7.1 had the best 
balance of charge for DNA complexation (at low polymer concentrations) with buffering 
capacity for endosomal release.  A window from 24% to 50% amine protonation in 
solution was identified, with the highest bioactivity at 33% ionization.  The best material 
was a copolymer of dimethylaminoisoprene (DMAI) and dipropylaminoisoprene (DPAI) 
(60:40 feed ratio) where the homopolymers of each of the monomers showed no 
transfection ability.  It would be interesting in future experiments to quaternize the 
homopolymers, particularly poly(diethylaminoisoprene) PEAI,  in the range of 24% to 
50% amine quaternization to explore if the enhancement that the copolymers benefited 
from could be transferred to the homopolymers.  In doing so an effective material may be 
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synthesized, while simultaneously verifying the defined ionization window (24-50%) that 
could be applied towards future material design (Scheme 5.1).  With the high level of 
control over the ionization of these materials, they may also be used in applications that 
range from smart materials for drug delivery or integrated into environmentally sensitive 
microfluidic devices.  
 
 
 
 
Scheme 5.1.  Quaternization of PEAI from 24% to 50% of the amines 
 
  
Another aspect of gene delivery that was explored was decreasing the toxicity of a 
material that possessed functionality already proven to impart high bioactivity in previous 
delivery materials developed by our lab.  This research utilized a Diels Alder 
cycloaddition of diethylaminoisoprene (DEAI) with fumaric acid to afford a monomer 
that could be polymerized in step growth fashion with a diol or diamine.  Previous 
attempts to incorporate an amino diacid into a material via this route were only successful 
as a 50% copolymer with an unfunctionalized diacid, where above this feed the material 
crosslinked.  By designing a diacid with a tetrasubstituted doublebond, the crosslinking 
reaction was prevented, and an amine containing homopolymer was synthesized.  The 
solubility of the resulting polymer could also be controlled by incorporating a 
hydrophobic or hydrophilic diol.  When compared to a nondegradable commercially 
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available delivery vector, use of the polyester scaffold was successful in lowering the 
materials toxicity.  Unfortunately, the transfection ability was nominal, despite elevated 
polymer concentrations.  This result was attributed to the low amine content in a low 
molecular weight homopolymer. 
 The last focus was placed on enhancing the cellular uptake of the polyplex by 
using a peptide mimic of transmembrane proteins found in viral based delivery systems.  
These natural peptides have higher concentrations of arginine at their active site.  The 
functionality of arginine is a guanidine moiety and has been shown in some materials to 
increase membrane translocation.  In an attempt to further enhance an efficient delivery 
material, poly(diethylaminoisoprene) (PEAI), previously developed in our lab, an 
analogue to diethylaminoisoprene (DEAI) that replaced the diethylamine with guanidine 
was designed.  Numerous strategies were employed, and two intermediate targets proved 
successful to ultimately synthesizing the guanidine monomer.  The first was 
bromoisoprene, where nucleophilic substitution with a diboc protected guanidine 
afforded the target monomer.  This strategy, however, was plagued with low yields and 
instability of the bromoisoprene.  The second pathway targeted a tosylated 
hydroxyisoprene that would be reactive towards an identical nucleophilic substitution 
with diboc protected guanidine.  The hydroxyisoprene and subsequent tosylation were 
successful in 2 days, and the monomers were stable at 4 oC for over a month.  Utilizing 
either strategy yielded the target monomer.  The polymerization of this monomer was 
successful, but deprotection steps have yielded crosslinked materials.  Future studies will 
focus on varying the deprotection conditions, specifically utilizing carbocation 
scavengers to prevent cationic polymerization when the t-butyl carbocation is produced. 
108 
 
 
tosylisoprene
(Boc)2guanidine
pthalamide
sodium azide
carboxylic
acid/acid halide alcohol
R'CO2R
R'OR
N
O
O
R R NH2
hydrazine
NaOH
R N3
R (Boc)2guanidine
tosylation
alkyl
halide
OR
2o or 3o
amine
R NR'2R'OR
isocyanate
R'N
O
OH
epoxide
OH
R'OR
 
Figure 5.1.  Elaboration of 2-functionalized isoprene; the diene is serving as a(n) left: 
nucleophile; right: electrophile 
  
 
The hydroxyisoprene tosylate has proven to be a powerful intermediate for 
developing 2-funtionalized isoprenes (Figure 5.1), which previously had no general 
method for synthesis.  Preliminary studies have shown that substitution was possible with 
guanidine as well as a secondary amine nucleophile.  It is thought that a wide range of 
nucleophiles may be selected, and a library of 2-functional dienes could be rapidly 
synthesized.  Not only can the tosylate electrophile be used, but the hydroxyisoprene 
itself could be used as a nucleophile to generate ethers, esters, etc.  Another potential 
study with the hydroxyisoprene monomer is the polymerization to form a polyol and 
from which grafting from the backbone would generate cylindrical brushes.  Two 
possible targets for initial grafting studies could be poly(caprolactone) (degradable) and 
poly(N-isopropylamide) (thermally responsive) (Scheme 5.2).  Preliminary radical 
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polymerization attempts of hydroxyisoprene resulted in crosslinking reactions.  Further 
attempts will focus on protecting the hydroxyl group as an acetate or as a silyl ether 
followed by polymerization.  The cylindrical brushes would be valuable due to their 
unique solution properties for fundamental physical studies as well as potentially useful 
drug delivery systems. 
 
Scheme 5.2.  Cylindrical brush formation by a) ring opening of caprolactone or b) ATRP 
polymerization of N-isopropylamide 
  
a) 
b) 
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2.02.22.42.62.83.03.23.43.63.84.04.24.44.64.85.05.25.45.65.8
f1 (ppm)
 
1H of 2-bromo-N,N-dimethylprop-2-en-1-amine 
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2.02.53.03.54.04.55.05.56.06.57.0
f1 (ppm)
 
1H of N,N-dimethyl-2-methylenebut-3-en-1-amine (Dimethylaminoisoprene; DMAI) 
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13C of N,N-dimethyl-2-methylenebut-3-en-1-amine (Dimethylaminoisoprene; DMAI) 
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2.02.53.03.54.04.55.05.56.06.57.07.5
f1 (ppm)
 
1H of poly(2-(N,N-dimethylaminomethyl)-1,3-butadiene) (PMAI) 
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13 
 13C of poly(2-(N,N-dimethylaminomethyl)-1,3-butadiene) (PMAI) 
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1H of 2-bromo-N,N-diethylprop-2-en-1-amine 
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13C of 2-bromo-N,N-diethylprop-2-en-1-amine 
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1H of N,N-diethyl-2-ethylenebut-3-en-1-amine (Diethylaminoisoprene; DEAI) 
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13C of N,N-diethyl-2-ethylenebut-3-en-1-amine (Diethylaminoisoprene; DEAI) 
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1H of poly(2-(N,N-diethylaminomethyl)-1,3-butadiene) (PEAI) 
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13C of poly(2-(N,N-diethylaminomethyl)-1,3-butadiene) (PEAI) 
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1H of 2-bromo-N,N-propylprop-2-en-1-amine 
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13C of 2-bromo-N,N-propylprop-2-en-1-amine 
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1H of N,N-dipropyl-2-ethylenebut-3-en-1-amine (Dipropylaminoisoprene; DPAI) 
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13C of N,N-dipropyl-2-ethylenebut-3-en-1-amine (Dipropylaminoisoprene; DPAI) 
  
126 
 
 
 
 
1.01.52.02.53.03.54.04.55.05.5
f1 (ppm)
 
1H of poly(2-(N,N-dipropylaminomethyl)-1,3-butadiene) (PPAI)  
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13C of poly(2-(N,N-dipropylaminomethyl)-1,3-butadiene) (PPAI) 
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1H of poly(2-(N,N-dimethylaminomethyl)-3-methyl-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-3-methyl-1,3-butadiene) (20:80) (MePr-20) 
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1H of poly(2-(N,N-dimethylaminomethyl)-3-methyl-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-3-methyl-1,3-butadiene) (40:60) (MePr-40) 
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1H of poly(2-(N,N-dimethylaminomethyl)-3-methyl-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-3-methyl-1,3-butadiene) (54:46) (MePr-54) 
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1H of poly(2-(N,N-dimethylaminomethyl)-3-methyl-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-3-methyl-1,3-butadiene) (60:40) (MePr-60) 
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13C of poly(2-(N,N-dimethylaminomethyl)-3-methyl-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-3-methyl-1,3-butadiene) (60:40) (MePr-60) 
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1.01.52.02.53.03.54.04.55.05.5
f1 (ppm)
 
1H of poly(2-(N,N-dimethylaminomethyl)-3-methyl-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-3-methyl-1,3-butadiene) (80:20) (MePr-80) 
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1H of poly(2-(N,N-diethylaminomethyl)-1,3-butadiene-co-2-(N,N-dipropylaminomethyl)-
1,3-butadiene) (20:80) (EtPr-20) 
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0.51.01.52.02.53.03.54.04.55.05.5
f1 (ppm)
 
1H of poly(2-(N,N-diethylaminomethyl)-1,3-butadiene-co-2-(N,N-dipropylaminomethyl)-
1,3-butadiene) (40:60) (EtPr-40) 
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1H of poly(2-(N,N-diethylaminomethyl)-1,3-butadiene-co-2-(N,N-dipropylaminomethyl)-
1,3-butadiene) (60:40) (EtPr-60) 
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13C of poly(2-(N,N-diethylaminomethyl)-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-1,3-butadiene) (60:40) (EtPr-60) 
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1H of poly(2-(N,N-diethylaminomethyl)-1,3-butadiene-co-2-(N,N-dipropylaminomethyl)-
1,3-butadiene) (80:20) (EtPr-80) 
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DSC of poly(2-(N,N-dimethylaminomethyl)-1,3-butadiene) (PMAI) 
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DSC of poly(2-(N,N-diethylaminomethyl)-1,3-butadiene) (PEAI) 
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DSC of poly(2-(N,N-dipropylaminomethyl)-1,3-butadiene) (PPAI) 
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DSC of poly(2-(N,N-diethylaminomethyl)-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-1,3-butadiene) (20:80) (EtPr-20) 
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DSC of poly(2-(N,N-diethylaminomethyl)-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-1,3-butadiene) (40:60) (EtPr-40) 
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DSC of poly(2-(N,N-diethylaminomethyl)-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-1,3-butadiene) (60:40) (EtPr-60) 
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DSC of poly(2-(N,N-diethylaminomethyl)-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-1,3-butadiene) (80:20) (EtPr-80) 
 
 
 
 
146 
 
DSC of poly(2-(N,N-dimethylaminomethyl)-3-methyl-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-3-methyl-1,3-butadiene) (20:80) (MePr-20) 
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DSC of poly(2-(N,N-dimethylaminomethyl)-3-methyl-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-3-methyl-1,3-butadiene) (40:60) (MePr-40) 
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DSC of poly(2-(N,N-dimethylaminomethyl)-3-methyl-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-3-methyl-1,3-butadiene) (54:46) (MePr-54)
149 
 
 
DSC of poly(2-(N,N-dimethylaminomethyl)-3-methyl-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-3-methyl-1,3-butadiene) (60:40) (MePr-60) 
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DSC of poly(2-(N,N-dimethylaminomethyl)-3-methyl-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-3-methyl-1,3-butadiene) (80:20) (MePr-80) 
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TGA of poly(2-(N,N-dimethylaminomethyl)-1,3-butadiene) (PMAI) 
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TGA of poly(2-(N,N-diethylaminomethyl)-1,3-butadiene) (PEAI) 
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TGA of poly(2-(N,N-dipropylaminomethyl)-1,3-butadiene) (PPAI) 
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TGA of poly(2-(N,N-diethylaminomethyl)-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-1,3-butadiene) (20:80) (EtPr-20) 
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TGA of poly(2-(N,N-diethylaminomethyl)-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-1,3-butadiene) (40:60) (EtPr-40) 
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TGA of poly(2-(N,N-diethylaminomethyl)-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-1,3-butadiene) (60:40) (EtPr-60) 
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TGA of poly(2-(N,N-diethylaminomethyl)-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-1,3-butadiene) (80:20) (EtPr-80) 
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TGA of poly(2-(N,N-dimethylaminomethyl)-3-methyl-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-3-methyl-1,3-butadiene) (20:80) (MePr-20) 
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TGA of poly(2-(N,N-dimethylaminomethyl)-3-methyl-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-3-methyl-1,3-butadiene) (40:60) (MePr-40) 
 
 
 
 
160 
 
 
TGA of poly(2-(N,N-dimethylaminomethyl)-3-methyl-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-3-methyl-1,3-butadiene) (54:46) (MePr-54) 
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TGA of poly(2-(N,N-dimethylaminomethyl)-3-methyl-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-3-methyl-1,3-butadiene) (60:40) (MePr-60) 
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TGA of poly(2-(N,N-dimethylaminomethyl)-3-methyl-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-3-methyl-1,3-butadiene) (80:20) (MePr-80) 
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GPC of poly(2-(N,N-dimethylaminomethyl)-1,3-butadiene) (PMAI) 
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GPC of poly(2-(N,N-diethylaminomethyl)-1,3-butadiene) (PEAI) 
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GPC of poly(2-(N,N-dipropylaminomethyl)-1,3-butadiene) (PPAI) 
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GPC of poly(2-(N,N-diethylaminomethyl)-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-1,3-butadiene) (20:80) (EtPr-20)
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GPC of poly(2-(N,N-diethylaminomethyl)-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-1,3-butadiene) (40:60) (EtPr-40)
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GPC of poly(2-(N,N-diethylaminomethyl)-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-1,3-butadiene) (60:40) (EtPr-60) 
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GPC of poly(2-(N,N-diethylaminomethyl)-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-1,3-butadiene) (80:20) (EtPr-80) 
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GPC of poly(2-(N,N-dimethylaminomethyl)-3-methyl-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-3-methyl-1,3-butadiene) (20:80) (MePr-20) 
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GPCof poly(2-(N,N-dimethylaminomethyl)-3-methyl-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-3-methyl-1,3-butadiene) (40:60) (MePr-40) 
172 
 
 
 
GPC of poly(2-(N,N-dimethylaminomethyl)-3-methyl-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-3-methyl-1,3-butadiene) (60:40) (MePr-60) 
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GPC of poly(2-(N,N-dimethylaminomethyl)-3-methyl-1,3-butadiene-co-2-(N,N-
dipropylaminomethyl)-3-methyl-1,3-butadiene) (80:20) (MePr-80) 
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DLS and ζ-potential measurements of the homo- and copolymers complexed with 
pCMV-Luc 
 
 
 
 
 
 
 
 
 
DLS was done to examine if the complex size would allow for an endocytotic 
pathway.  The experiments showed that multiple populations formed with one population 
being 150-250 nm and the other > 1000 nm.  The smaller population is most likely the 
group that translocates into the cell and labeling studies will be conducted in the future to 
further explore the uptake pathway.  For each material there was also a rapid complex 
size increase at low concentrations where the polymer seems to induce aggregation.    
This clustering effect has been seen in other polymer systems, most notably poly(lysine), 
and is strongly dependent on the characteristics of the individual polymer.a 
 
aTang, M. X.; Szoka, F. C. Gene Ther 1997, 4, 823-832.  
  
Polymer 
Complex Diametera 
(nm) 
    2c  4 c  10 c 
 
ζ-Potentialb 
(mV) 
2 c 4 c   10 c 
 
PMAI 244 219 197 
529 403 416 
- - - 
144 184 108 
381 265 187 
473 410 313 
200 100 100 
417 305 202 
- - - 
368 367 507 
460 245 228 
373 310 332 
 
24 19 24 
11 7.3 13 
- - - 
-5.9 1.1 3.2 
-12 5.5 3.0 
15 22 16 
17 24 29 
19 5.7 11 
- - - 
-33 -18 11 
-18 4.2 4.4 
11 12 17 
 
PEAI 
PPAId 
MePr-20 
MePr-40 
MePr-54 
MePr-60 
MePr-80 
EtPr-20d 
EtPr-40 
EtPr-60 
EtPr-80 
a: Determined by dynamic light scattering at 173o. b: Determined on 
a zetasizer with a low volume flow cell. c: N/P ratio d: Polymer did 
not remain soluble during the DLS and ζ-potential experiments. 
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1H of 2-(N,N-diethylaminomethyl)-3-methyl-1,3-butadiene  
  
177 
 
 
 
1H of 4-((diethylamino)methyl)-5-methylcyclohex-4-ene-1,2-dicarboxylic acid 
 
  
178 
 
 
 
 
13C of 4-((diethylamino)methyl)-5-methylcyclohex-4-ene-1,2-dicarboxylic acid 
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0123456789101112
f1 (ppm)
 
1H of 4,5-dimethylcyclohex-4-ene-1,2-dicarboxylic acid   
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30507090120150180
f1 (ppm)
 
13C of 4,5-dimethylcyclohex-4-ene-1,2-dicarboxylic acid 
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1H of Poly(octanediol 4,5-dimethylcyclohex-4-ene-trans-1,2-dicarboxylate-co-octanediol 
4-(N,N-diethylaminomethyl)-5-methyl-cyclohex-4-ene-trans-1,2-dicarboxylate) (80:20) 
(PI-20) 
 
  
182 
 
 
 
 
1H of Poly(octanediol 4,5-dimethylcyclohex-4-ene-trans-1,2-dicarboxylate-co-octanediol 
4-(N,N-diethylaminomethyl)-5-methyl-cyclohex-4-ene-trans-1,2-dicarboxylate) (60:40) 
(PI-40) 
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1.01.52.02.53.03.54.0
f1 (ppm)
 
1H of Poly(octanediol 4,5-dimethylcyclohex-4-ene-trans-1,2-dicarboxylate-co-octanediol 
4-(N,N-diethylaminomethyl)-5-methyl-cyclohex-4-ene-trans-1,2-dicarboxylate) (40:60) 
(PI-60) 
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1H of Poly(octanediol 4,5-dimethylcyclohex-4-ene-trans-1,2-dicarboxylate-co-octanediol 
4-(N,N-diethylaminomethyl)-5-methyl-cyclohex-4-ene-trans-1,2-dicarboxylate) (20:80) 
(PI-80) 
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1.01.52.02.53.03.54.04.5
f1 (ppm)
 
1H of Poly(octanediol 4,4-(N,N-diethylaminomethyl)-5-methyl-cyclohex-4-ene-trans-1,2-
dicarboxylate) (PI-100) 
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1H of Poly(tetraethyleneglycol 4,5-dimethylcyclohex-4-ene-trans-1,2-dicarboxylate) (PII-
0)  
187 
 
 
 
 
 
 
 
1H of Poly(tetraethyleneglycol 4,5-dimethylcyclohex-4-ene-trans-1,2-dicarboxylate-co-
tetraethyleneglycol 4-(N,N-diethylaminomethyl)-5-methyl-cyclohex-4-ene-trans-1,2-
dicarboxylate) (40:60) (PII-60) 
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1H of Poly(tetraethyleneglycol 4-(N,N-diethylaminomethyl)-5-methyl-cyclohex-4-ene-
trans-1,2-dicarboxylate) (PII-100) 
189 
 
 DSC of Poly(octanediol 4,5-dimethylcyclohex-4-ene-trans-1,2-dicarboxylate) (PI-0) 
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DSC of Poly(octanediol 4,5-dimethylcyclohex-4-ene-trans-1,2-dicarboxylate-co-
octanediol 4-(N,N-diethylaminomethyl)-5-methyl-cyclohex-4-ene-trans-1,2-
dicarboxylate) (80:20) (PI-20) 
191 
 
DSC of Poly(octanediol 4,5-dimethylcyclohex-4-ene-trans-1,2-dicarboxylate-co-
octanediol 4-(N,N-diethylaminomethyl)-5-methyl-cyclohex-4-ene-trans-1,2-
dicarboxylate) (60:40) (PI-40) 
  
192 
 
DSC of Poly(octanediol 4,5-dimethylcyclohex-4-ene-trans-1,2-dicarboxylate-co-
octanediol 4-(N,N-diethylaminomethyl)-5-methyl-cyclohex-4-ene-trans-1,2-
dicarboxylate) (40:60) (PI-60) 
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DSC of Poly(octanediol 4,5-dimethylcyclohex-4-ene-trans-1,2-dicarboxylate-co-
octanediol 4-(N,N-diethylaminomethyl)-5-methyl-cyclohex-4-ene-trans-1,2-
dicarboxylate) (20:80) (PI-80) 
 
 
 
194 
 
DSC of Poly(octanediol 4-(N,N-diethylaminomethyl)-5-methyl-cyclohex-4-ene-trans-1,2-
dicarboxylate) (PI-100) 
 
 
 
195 
 
DSC Poly(tetraethyleneglycol 4,5-dimethylcyclohex-4-ene-trans-1,2-dicarboxylate) 
(PII-0) 
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DSC of Poly(tetraethyleneglycol 4,5-dimethylcyclohex-4-ene-trans-1,2-dicarboxylate-co-
tetraethyleneglycol 4-(N,N-diethylaminomethyl)-5-methyl-cyclohex-4-ene-trans-1,2-
dicarboxylate) (40:60) (PII-60) 
 
 
 
197 
 
DSC of Poly(tetraethyleneglycol 4-(N,N-diethylaminomethyl)-5-methyl-cyclohex-4-ene-
trans-1,2-dicarboxylate) (PII-100) 
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TGA of Poly(octanediol 4,5-dimethylcyclohex-4-ene-trans-1,2-dicarboxylate) (PI-0) 
 
 
199 
 
TGA of Poly(octanediol 4,5-dimethylcyclohex-4-ene-trans-1,2-dicarboxylate-co-
octanediol 4-(N,N-diethylaminomethyl)-5-methyl-cyclohex-4-ene-trans-1,2-
dicarboxylate) (80:20) (PI-20) 
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TGA of Poly(octanediol 4,5-dimethylcyclohex-4-ene-trans-1,2-dicarboxylate-co-
octanediol 4-(N,N-diethylaminomethyl)-5-methyl-cyclohex-4-ene-trans-1,2-
dicarboxylate) (60:40) (PI-40) 
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TGA of Poly(octanediol 4,5-dimethylcyclohex-4-ene-trans-1,2-dicarboxylate-co-
octanediol 4-(N,N-diethylaminomethyl)-5-methyl-cyclohex-4-ene-trans-1,2-
dicarboxylate) (40:60) (PI-60) 
 
 
 
202 
 
 
TGA of Poly(octanediol 4,5-dimethylcyclohex-4-ene-trans-1,2-dicarboxylate-co-
octanediol 4-(N,N-diethylaminomethyl)-5-methyl-cyclohex-4-ene-trans-1,2-
dicarboxylate) (20:80) (PI-80) 
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TGA of Poly(octanediol 4-(N,N-diethylaminomethyl)-5-methyl-cyclohex-4-ene-trans-
1,2-dicarboxylate) (PI-100) 
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TGA of Poly(tetraethyleneglycol 4,5-dimethylcyclohex-4-ene-trans-1,2-dicarboxylate-
co-tetraethyleneglycol 4-(N,N-diethylaminomethyl)-5-methyl-cyclohex-4-ene-trans-1,2-
dicarboxylate) (40:60) (PII-60) 
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TGA of Poly(tetraethyleneglycol 4-(N,N-diethylaminomethyl)-5-methyl-cyclohex-4-ene-
trans-1,2-dicarboxylate) (PII-100) 
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TGA of Poly(tetraethyleneglycol 4,5-dimethylcyclohex-4-ene-trans-1,2-dicarboxylate-) 
(PII-0) 
 
 
 
 
  
207 
 
 
GPC of Poly(tetraethyleneglycol 4,5-dimethylcyclohex-4-ene-trans-1,2-dicarboxylate-co-
tetraethyleneglycol 4-(N,N-diethylaminomethyl)-5-methyl-cyclohex-4-ene-trans-1,2-
dicarboxylate) (40:60) (PII-60) 
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GPC of Poly(tetraethyleneglycol 4-(N,N-diethylaminomethyl)-5-methyl-cyclohex-4-ene-
trans-1,2-dicarboxylate) (PII-100) 
 
 
  
209 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix C 
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1H of 3-Methyl-2,5-dihydrothiophene-1,1-dioxide 
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1H of 3-Bromomethyl-2,5-dihydrothiophene-1,1-dioxide 
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1H of 2-Bromomethyl-1,3-butadiene 
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1H of 1,3-(ditertbutoxycarbonyl)guanidinoisoprene 
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13C of 1,3-(ditertbutoxycarbonyl)guanidinoisoprene 
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1H of poly(1,3-(ditertbutoxycarbonyl)guanidinoisoprene) 
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1H of 1-((2-bromoallyl)oxy)-4-methylbenzene 
  
217 
 
 
 
 
1H of ((2-bromoallyl)oxy)trimethylsilane 
  
218 
 
 
4.04.55.05.56.06.57.0
f1 (ppm)
 
1H of 2,5-dihydrothiophene-3-carboxylic acid 1,1-dioxide 
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13C of 2,5-dihydrothiophene-3-carboxylic acid 1,1-dioxide 
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1H of hydroxyisoprene (sulfone method) 
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1H of hydroxyisoprene (chloroprene method) 
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1H of hydroxyisoprene (crude) (ring-opening method) 
  
223 
 
 
 
1H of tosylisoprene (ring-opening method) 
  
ether 
ether 
224 
 
 
 
1H of crude poly(1,3-(ditertbutoxycarbonyl)guanidinoisoprene) (ring-opening method) 
 
 
 
Boc2GIso tosylIso 
